var title_f13_18_13600="Head tilt chin lift";
var content_f13_18_13600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Head-tilt-chin-lift maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    One of the rescuer's hands is used to tilt the head, extending the neck. The index finger of the rescuer's other hand lifts the mandible outward, raising the chin. Head tilt should not be performed if cervical spine injury is suspected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13600=[""].join("\n");
var outline_f13_18_13600=null;
var title_f13_18_13601="Pulsed wave Doppler LV outflow";
var content_f13_18_13601=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulsed wave Doppler echocardiography flow signals from the left ventricular outflow tract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 277px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEVAXMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAK9xYJniNMZ9K8Or20EDPtSZLS6ipFBgARqB3AFPCQjkxrz7VGMk8HoPzpck5z0HehS8yVFDmVDk+WmDTxGnZEBBycCojlz8oAA9KB2JP4UnqHKSjy88IF5wMipM8kKg9gBVd8g5zweM1ueFdI/taa8kkYRW1qoDuXx8x6daPhFa5llwAwAH0oEwC4wCMenQ1Lf26W15JGjl1Xgv2qnKDtxnaSRg47ZpdB2ROJsY6EntikaVAfurnv8tWtWu7O5uFewtfsyBQpXORkdTVAHJOMZXt1zQm+gnFbsmaTIYBEJA6laQSRqpPlIT3yvQ1LqOn3FpptvdyIAlyAYyD6nvXsMPgfwlpei2UmuXF0bqWBZXaJCyjP4U3K241DpY8bWVWJ/dx46fcppkC52pCMdSVHNd98TPDGm+HtRt00qRzbzQiUb+ozXAMFxyM5NVZMm1hTNgYMUQ54+Sk3kc7IiD/s1G/LAL82OlIWIYk4wPT1qblWQ97gsd3lxg/7tIHB+YxxjH+zUeQVwePekDYHIzihIbROHG5RsiI/3a8p8cY/4Sm92gAfJwOn3Fr1BCcnAxxmvLPGf/Iy3n/AP/QFqloEVrcxKKKKCwooooAKKKKACiiigAooooA3tMt7d7GNpISzHOSB7mirWjRSNpsJWTA54/wCBGiu2N+VHNLd6nL0UUVxHSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFe2lf7vXFeJV7cp+QmgTEC89e1KrEDaBxS+4wOOtNzzheRSaROwv40E9MjH0oPoSTz2oPOec0kxvUaTuGB0HNaFtHc29ktyUlS2kbIkGVDH61SRQ6uGOAQRXW2OpDU/DVtpsp/f2/yJGAAu31zTavuJlHV4VEFuYiDJMuZO4b3BrJu7eRY2lQ79owA3f2r1XS303XvDH2aa0hjuYQYojCQJi3+0PT3rim0SbTZi160flcg5bO361DsS00YWpw2MAtmsLlp98YaQEY2N3AqGA+WfNVsueFyela974cuIlimVAIJl3wyA8OtZ0tsbZykw8skZC9z70QTsNsjKzvHIDukUD5u+339q7bTvin4k0/So9Og+xyW8cflhpVyxFcfYajc2lvdQW5CpdYEgIznFVGGSVYdutaTvawlpsbfijxXqHiW5S41ARIyoIwEHGBWCkrujZUgZ70vyk56j09adjhmJ49KmCsrFt9xN2PujFNwQMHoe1PGRjoAaaQSw7iqtqK+om3JxigvhuVpxyGHc0xmI69DUj3AkgDHFeW+Nf+RmvO33P/QFr1HGc15d41/5Ga8/4B/6AtNb3GlYw6KKKYwooooAKKKKACiiigAooooA6rRYy2mQnfj73H/AjRUugo50mAqoI+b/ANCNFdsJe6jkle7OQoooriOsKKKKACiiigAooooAKKKKACiiigAooooAK9txkEE4zXiVe2Hpilr0FIOvuRwKT72ccGlKngj8QKdg4JxRcmwi8gDI2+tKAdmdvTqRSdM09SAh/vUD2RJZNEt1BJco5tw/7xOm9fSprmWFdRlktFaKBj8ibvuj61PpthBcx3jXF2LZoUDRBhnzD6e1UFP3uQfUetEyT0/4brY3H2m9vUja4gGAM4DD/axVLWDpeo+IY7S0dI7KQHfI/wB2Jvr1rD8AXMcWqzLPKyI6YMY/jrqNHFrZ63I4WD7NI2ZoG5GPr2rOTtcfZFjWfD1tbaP5EniaxRYYyVXPLj0FYXhr4ca94iSO6hQLZv8AdnlOAR6j1ro/E+saZbSS/a/C0EsRQhH+0dvpiub8N/EXXdDK29nLHLp+TttZhwi+gNF2tSly9T0LwZ8M/DBvpYLjVF1O9tj+9ihOFQ+5rnfG/hiCbxpbmz0mSz0UfuzIAQJGA7Zrc8GfEnwpaX0ss2mLo97P/rniHySH1rD8ceIUj8X28ll4ge90Rv3xhJysbHtWeOcnQqexvfldu97f5nRBUlUj/LdbnA6dFYT+LmtZ4mW080xBc85q42mW1kmu3V8j/Z7RvLgQHBZieKpaleeHYmuru1vZnuml8xFCHrnoKl8a6/Fq2m6bp9kD5zkT3JxgDHQGvnZTxWIdJUeZKSUZXurWs2/mrq53KFGlzudtLtbO/SxYuBouhSabZ6pBPc314odhH0iVumauvpek2HiGLTp0lmlucNEU6BT61XvNQ8PamtrearcNb3ECKj4GdwFZsHiJNU8awamytBpduBHFuGCQO9c8KWLqXTc1K0uborr4eX/gbo1lKhCztG11bvbrf/gkfiqfS7fUX07TbWZZ4GxLKfu/QVjY3ADI+man1S8jv9b1C6gyYJZfkJ4qCRRkc19Jl9OdPDQjNtuybu7u7/rY8rEyjKrLkSS6WEIx3ry7xqMeJrwf7n/oC16nt+YgnAHNeWeNefE15/wD/wBAWu1GNzDoooqhhRRRQAUUUUAFFFFABRRRQB2fh/zP7It9oGPm7/7RopPD8e7SID5hH3uM/wC0aK7YJ8q0OeW7ONoooriOgKKKKACiiigAooooAKKKKACiiigAooooAK9uHY4zivEa9uONuDmgTAZAJxjceaAMgnGSKdjawBz045prbgORwTUt9BDlHGT26k10PhWCzv459JniJnm/eR3CJudSP4cdh71z8ZIyDkVp6XrdzpWm3NvZhY/OPzS/xD2zVa2sg6jtX0PUNJZft8JjidsK+dyt9D0rK6M/IK54yOtb11a6tcWUAuEuGg2bk3KSMeoqXS/CerXJiuINPnnhJycLjj8amT2sStyHwZFdyax/oajeVwWK52/hXvOj+A7GaO3u3C3E+Mz7zjP09K4jw/NbeFr6Zltzbm4UKUY7ix9j2rufDPibZczATxywgcx7vmFZu6epSaH+Lfh3Y39gBYWqifPOXzge1cdcfDLbaCGBV+0r97dkCu48Z+L5bDSobq2RfKkfb8xwQfXFcn4R1KO51maTW7oXTTnKGNyoUelU31QWu7HC6p4OktUla4PzKdq7PmBrmZdFvEgmnS2PkRHa74+WvfdX1RbvWIdNhgjn03PKRxnk/wC9Wf8AFTSpI/BUw020lgiRg77Txj0xTjJXsiLaHz7tG4/Ko+goj4RugB6n1p7qQQefmGcUjg4wwz6EVVmPYZsyQQqEe4BpThwNw6UA7eOv0oGQp7jPFDvsgQKu5jkAgDoKAqsvJ2j1pF+U7hnjqKB905HvQ0kABd5OTwvt1ryzxyu3xTegdPk/9AWvUkcgD1z+leXeOs/8JVfZGD8nT/cWpjuUtzAoooqygooooAKKKKACiiigAooooA7DQA50mDA4+b/0I0UaDn+yYOT/ABf+hGiuyMfdRzSbuzj6KKK4zpCiiigAooooAKKKKACiiigAooooAKKKKACvbwM5PUivEK9vO5QtAmKBuOV4xS5GSG4HpigYDAkZz1z0p65EZzjGep/lSurktjNpKnDFgORU9orT3dhEiB5HnUBex571F8u4YHPpW/4NjszrKyX4ciJd0PlnGx/U+1Uk+gj6TikCWttGWtfOSIBlEYKtx6Vkv4pu7G+a0ks0WFxiNo/6AV5nbeI1iv5op5Vu9/SfeVZfyrf0jXbe4lhtHeK5KnKPz8v1Nc7bSKTuZ3xA1G3kkSS6gihccB4OS3+8prnvCuqPDKbi3095YgwXKnmr/wAS7ySe58hkjIA3BkBbH41x+i3f2cn960UY7qMkmm27WFfU7r4lanlrHznLYXIGMY9j2rP8HXegG3kl1O3u/tLvhBC2P0rD1HWxd6VJZXCqyb96nGWz/vVl6VIz3CxsSUHXAxiiMriaR9HaLLFbxo1nKIYdnEbAF/qTWF4q8S3pSRbM/asKQISPlbjvXHaBfLcX8dnFdsyAfMyDGPbir1/JLHqJtdMlbeTgGWi9tWUzyO6lLyykrsJcllA6GoirfL8vB6Vv+MbS2sdbe3gikjkC5lD92Pce1YL5yqAc9sGtle10Q97ERbGPl6nn3pTzwvHtUhUYwxCt7VEVJbcc57VKuhoFHX170mGDDnIpyE4Yt0xTVUfebOafKFxSQMkjnsK8r8cNu8UXp/65/wDota9W2luAcV5R42x/wk97t6fJ/wCgLTWiHG1zCooooLCiiigAooooAKKKKACiiigDr9BWI6VBuJz83f8A2jRUWis40yEKikfNyf8AeNFdUYuyOeTV9zqDpNj5h/0K129v3S/4U7+y7D/nxtf+/K/4VZQMWbIK+op20g89D0rB6GhVOladtyLK1z/1xX/ClXS9PJ5sLXA6/uV/wq5ggMQelKoIIx3Hek9RXKy6Vp2R/oFow9DCv+FOOkacefsFr/35X/CrcfzsGbjFSZw3BHtUNj3KR0jTVYj7BaHI4/cr/hS/2Tpm0f8AEvtP+/K/4VfBJzwAfWgsQ4AXJxzxSvYEUF0jTif+QfaY/wCuK/4Up0jTcf8AHhaZ/wCuC/4VfTklhxgcilCtuO0g5qrX1HexROj6cFUjT7M56fuV/wAKP7H052AGnWYbuPJX/Cr6x4+8c05AAec9ODU6hcoJo2mc7tPsx6fuV/wobR9NP3dPsz7CFf8ACrwU4O7B9KkEe5RggDvQhN2M06RpnA/s2zB9fIX/AAq6VHH6c1LyY/l25zjmkMfJV2wcdqaeoJjUXcSMZWpEGAQCDnj6U4DdGQMDtSKBjaWGB+Bpbaom4iKmQBgkdTXf/DXSZBb3WvG3FzAT5HkgbmB9a4IDYnAAJ4H1r2z4WfatI8KfZpoHjeR/MdHQ5I9eKmc3oVHVs53xNaW0Vwn2ixW3WQfKicMfrXHfZpoLt2tfMiGeOTXtuo2KeIdiRZDqflK5IX/CvOPFllqGlXjrdosgBwroR096d0xbPQ4y5muWdw8ruT1yTzS2axkqHQnnkdhRdb1uMmQAv0xUMZeFyerg+tK1tQR0Gq2tmNFkbyXiv9wKEfd2/wCNY2jmRrlUDBFb5Wc8Cr1yLi/0qa9Sdf8AR8KyO3Jz6A8/lWdZ79hbZuX15IzU20HZrc9Q8NrFoxYSTwowG5pQmdw9M1iX+v2NxqFzLBJsuI2/d4HDVzP9q3Jg8prgqvTgVnFlUtIgZz0BPXNNp2EpX2Ok8XN/bka6whVHgURSoT8zn1A9K5PGCATnj171ctrSe82RW4aWfrtHJFV9gRmDD5gcH2NXTbt7w5Wa0K5Tkd3PenvltuDgr2NOwN4A7UMvpk8/lRcnVkXIJY4KjqKRdvlqO2cn2qXDFzhQO2aaVC5zwe/pS1GtRpAHz5JPY1yWueEG1TVJ7w3oiMu07PJ3YwoHXcPSuvU5wCMrjj0pyIVJYkEnoafmh3tocD/wgAC5Op49vs//ANlTT4AIYD+0f/IH/wBlXeABiwzyKMOSeR70NtbhzM4Q+AMNt/tLP/bD/wCypD4B5wNTy3YeR/8AZV3oG5yOBtHakIAOemepqr6XQ7s4Q+AMLu/tLj/rh/8AZU0eAsn/AJCJx/17/wD2Vd3tJIUDnrmlZH6kYI6ikrhzHBHwGN2BqWR6+R/9lR/wgYAy2pY/7Yf/AGVd6UKk7QSvpSNGx+baOePpQ3rYLnCf8IEc86j/AOQP/sqP+EC+YD+0hz/0w/8Asq7plOMN+lIAN44pphd2OJNh/ZJNjv8AO8kkb8bc556ZPrRVvXsDV7nLk/MP5Ciu6NNWWhzOWpsthnbdnIPFAHPNNI+dsdjyT3p4/PtXGdDFIJAPAHTNOQjJHPHSlRQMEn6U8AscKpJ9hTb0JfYaqlRwck9alC+nBHemxgB+c+4qRj+APas0yraXEb5m4PNDBgeGA96cOHyOc07bg8npQNIAPlwfm+lKowetKDwcAYNIAFKnqDxRshEkEE9wdsMbSOOgXvU02n3kLr51rKjMPlBHWun+Hwzqd10VhEdrEcD3q4uq29tBZ2E1/wD2rqM1zw6rxGM9zXz2Mzmrh8S6EafMkl3vqr+ll5npUMvjWoqo52v9xw8kDw/JICjnqG6igr5eFzkdc12yafayazq1zqMQlKyqi7zhQD6Uy7sNI006pNcW7zQ2wVgmcZzSp8R0LJOL5rLZdXbRa+fUcsqrXumranHRQyTsFhjeXHPyiggj5Rjjg13sNpaW95cJaRGES2fmgA9Ae2ar6dpul/8AErsmtS891E0hkz0A/rS/1jo3d4NrRrvs2769LdBvKqllZq5xq5KYGPrQq5+vbua66DSdN1K1insoHhjE5hYE8tjvV1bHSLW6ScJEskMoQIj7ifc0T4jw8dFGV9dLfd1EsprvV2t6nClWB+YbSORuHSul0nxnrWmzeZDes527cPyCK05bSyvtV1a6uIF8q1IX5pNoJ988Cmrp2iRvczSYmhjg84rE+dvsCKhcRYeSTqQley0XfTTf/If9k1435Wrepds/iPdRKzXFpHJKTneh21o6l428Oazbj+0LK8guQM+YhDBj6EVy+mWtnrVha6hbWTW8LybWRn3Ns9TjpXM3FxBc394bOMR2schjjwc5x3Oa9HC5hTxFV04RkpRve9tNbWerOathalGCnJqz2Og1zVbG8jC2dvDER38vbx+dc+eWzkZNWtItRe6jb2pbG9uT7V0P2bSryTUreG0miOnY3SseJPoKrG5nSwklCab0u7dFe138xYfBzrpyjY5i4guEhWaSJ1jIwGI4NNMdxDAkg3pE3APRTW58QLxZjodnbrIIWj8zG7CAD1Hc07xP5j+GdEWMsUJPygcGuShms6sKNSULe0k1vslfX10NamBUJTinflVzCa3mSONpI5BuPyseMn2pxsrncq+S/mN0XHP1rrrKJtb0uwLnLWMu6RSMfLVS31O5vLbxPq+n4kuIj5FtxkIB3Fc9XO6kZSh7PWLs9dNWlH773ZrTy1SSlzaPbTyu/uMOKHUdKvI5IVmt7hhtV1HPPamHTL93ZmgkYnknb39a3rS/vE8BXF3qFxvu4cMk0i87j2FN8Rarqcfg3S5obzy57l8SybOcHtVRzTFKfslCN+bkerte17rTawngqTjzc7ta+3T7zm4oZJWkEcbOU+8AOlENrcXOfs8LPg4OBW14JuRZ6nJbSOGS4QoWYcknvTvE1ze+HNLstKsZQl9POXkkxk7PWuvE5lWpYlYSEE5Sty9mne9/SxjRwcalJ1nK0Ve/6feYzabe4b/RZOPaoZ4ngwJkKM3QMOtdN4q1PUYNP8PxQXhQXL4mkC8sKp+PNy+ILFA2UFvjBHX3rHB5pXq1YQqRSUnJaN/Z3+8vEYGnThKUZN2t07nPsrAhVwF7igg/Lg5weaXIyAM5pSMcEMDjjPGa9xSb0PO0In7lOB796T7wyTtY1IeQq5BJpFBKsMZx0oeo1cjBP3V796c2d21RwR3oXlVK5AzzQyscbT1PT0ppBZnTeAvDJ8W+Iv7MeUwRJH5jOP5V6NB8E7O6DAanNGynlDycVzPwMk2+NpSJUQ+QQm88E4r322laK1ZhLaLdFvnYyZBFJtwk4suMVJXR47F8IdNZ5lGpTbIjh29KnT4M6a8pii1iTcRuweles3KxyuRDJZomQWbePnqK6sbSe5RxdW6x4wwDgHNLme6H7NPueJeLPhXa6J4dn1OLUzK8RwsbfxHPavLtjK4O7HIzX0h8VraFfAdyTLBKIG3Iyv8AMDXzhI+45z94jPuarm6oiUeV2OU11VbVrkkDJbsfYUUa6R/a1znH3h/IUV6UJ+6jCxqk8nIwc0KDuGOtOblzz3pM4PHXOBiuJ6mpJhiyherNtA9zXqPgXwFq9j4o0++1H7ELAIWbdICORxkV5YjkE5HyirP2u6cKpvLjb0A8w9KTbGmlqd3qfw612bUruW3FmsMkrMv70dCeKqJ8OfEDsVVrJmj6jzhxXK/aLvp9ruMDp+8NCz3CMzJdThm+9855qXfdhZPZv8Dsbb4Z69JdQrdPZxwO4EjiUZUetSal8M9Zg1K4i06Wzns0IEcrSjLDvXFtdXf3ftdwf+BnmnJPeDIW7uAPTeaHfYSS7s6v/hW/iHPAssdf9aKcvw48RBwdtiVyBt80cD1rlDeXXQ3k/HTDmnrfXZXBu5w3rvPSkwt5no0vgfXtEup10G4sp0lhAaR5RwT1FYuj/D/xFpk0U0Sae86NuyZhya5MXdyuAtzNj13nmni9ugMJcTEn/aPFZeyheUuVXlo/NeZp7R2Ubuy28jvl0LxxFBeGP+zWmmk3gtKMD8Kk8T+C/Ek2nxrFfWc02oIPtg80Dy8dFFefx3d3uDfaZs/75pGvLoOS08u49PmNcqyvCQfPGkr/AOX/AAxvLHYh+7zv8DvB4a8ZG6aZfsCj7MLZR54+Vajh8K+MYr+zuQLDdaQtFGPtAxz3rio765Zf9fNu9d5pftlxsP8ApEzY7ljij+zMKv8Al2v6/wCHD67W253+B6BD4K8S2vhnTxb3Nr9v+1GaeHz1AH41BqHhfxjfXUbbdPhhWTzGWKZR5hHqa4drm5k5NxJ9SxpRc3OAFnk/76NKWW4Xn5/Zpv0BY2va3Oz0FdB8Zm8uJXh05opRjyTKuwn1PrWhZeFvEE/gbXINQNl/a1ywS2RZEConcAZry5rmc9ZpP++jQbiUgDzHPfljilSyzBwd/Zr7hyx1dq3OzvYvC2uaH4Xks7W3E99cr5SqkybU9WJzxWPafDXXra2igFvCdoyx89OWPXvXM+dLt5kc46cnml86U8mWQZHPzGtsPhVRnUqR1c3dmM6znCFN7RO80X4eaorXFxcyR208C7rcCVD5jenWma14X8Y6la/Z2+ywRyged5TIHf2zurhkllGcSOOP7xprPI5/10ufXzCP60VsJRryjOrFNra5VLETopxpyaT3/r/I7C+8DeJb67tpp4oFW1i8mKMSrnHqTmt/Q/DHiFpoLS9ksrSwiQlZHZXO7sOteY+fMp/183I/56GkMkwIP2mcH/rq3+NRPA0Z01RnBOK2XYccVUjNzjJ3fod5F4U8XxnUGV7VZboFAQ6gKvqOetR6F4J8SaFFss/ICty6tIpDk9SRmuIeabdg3Fxkd/Nbj9aaZp+Qbm69c+c3+NV9RoKMoqCs7X80tvuD61VbUuZ3W3zO8u/AviTX761t9duLO30hX3PHA4A+ppdf8Da9dhLCKS2fTraTMLhxmQetcK0k23m6ucEdPOb/ABpv2iddgS5uuOMec3+NFPB0oRUIwSUXdeT7+op4qpNuUpO7Vvl2Ovg8Ba9FcJKsUW5DuB8wdadf+A/EupayNQ1B7dycRqqyACJO5rjzcXSkj7XdYH/TZv8AGk865xj7Zd4P/TZq1dFOaqNLmWifVXIjWai4J6Pod54k8A63PqtlFaT29xp1ioeF/MGXbvVXVPAvibUtSW7u1tiVTYiiQfKK44TXAXat5cge0pokubvOBeXf/f0/41McLCDUlFXV7fPf7+pU8ROSabetvw2Omm+HHiJom2rbgnAH70cV1HjjwTf6guhjTI7QG3tvLnKuAS3vXl/2m7P/AC+XX/f00Ce7B4vroev7w1rDnV2rGLaasdU3w68Q87Y7f6+YKZJ8OPERJIjt+B/z1Fcw91fbeL26zn/noaa15eZy1/cg/wDXQ0JS8gukdvdfDPVY9MsriCW3ku5SRPCZB+7rNb4deIy+fJt8k9pRXMm5uxuzfXOT6yGlS8v9rf6fcqQevmGnDnemn4jvHc6iPwB4pil8yFYYTjGUmANaKfD/AMSf2E159uP9oLJtFqbjhl9a4Y6jfMxAvrrAHP7w0h1LUPlc3tzgH++acrvdIFK2iudW3gvxocgP8v8A18Un/CFeM9qBDg5/5+K5ddU1BGYC/ueec7zxTBqOonJ+33OAc/fPNKztrFD5n3ZPqseq2d3LY6lPIXTmSPzMis0qfMRsZAOadNLJLJ5kzs8rdSx60xg3mYP1rRRS1sTdvc5XXctq1ySVyW7/AEFFN1vadVuDyPm9PYUV3xiuVHO9zdON53ccmlAC4PUGmsMk5pRyDx261yW1NyQAFsY5atVtB1ZIBIdKuxH1DeWeRWXE+0o7DlSGA969Mh+NPiRYo4hFamFFC42DkCpafa4k11Zxb6DrbReYNJvDGeSfLPFSQeGtduMtDpF2UxnJQ9K7iX41eI3kDRxW6Q9k2Cnf8Ls8QC8Eogg+zgYMQUcVPM1uitO5w3/CM68YvMGj3ezOD8hzU0PhXxBJZT3P9kXQjiOHBU5P0rs7f40+IEE2+OFg/wBz5R8lMX4zeJCqo6w5HfaOaV2+g36nAPpWpQt5c2m3iPjoYzVy58Na5aQxz3Ok3SRuMqwQnj6V38Hxn1cLi5s7aaU9TsHFQWvxf1+DzhKIpRK4ZQ4BCD+6KfXYNO5xN14f1izgimvNLukhl+4QhOaij0nU51PkabesFOMiI8V3tr8X9ZhnuZLiFLhJGGxGUERj2p8/xn1oKv2a2ghUZ3EIOalvXVByp63OBTStUct/xLL1vL+9iI/LTjpmorF5p0u92Zxu8o4ruv8AhcOvfZUWOKBJGOXfYPmFSN8YNbeeLMVsIQOY9gw3vUqUb7MLLucBLpmoQxgy6bdxq3Klojz9Kli0TVngSeHTLtoScBgnU/Su8X4u6y90XkhtpIO0bIOKfc/GHWPLdLWCCJyOPkHFW2n0E0l1PP4tL1OfcY9MvGAOG/dHg0z+zb8MxNjdgg7T+6PX0rvW+LuutHGsS26OPvkRj5qkX4t60EiDRW5Ctlz5Yyf0oi0+jHZdzhP7E1UHJ0y94GSPLNM/s29GN1ncjJwMxNz+ld3N8W/EG5mDQ5zlQEGAKdF8XdaE6u8Vu0YByhQcn1zU+Vn+AKz6nD3eiana5NxY3UaAbtxjOMU0aXemJZPstyYj0bymwfpxXZRfE/xBul3yJNFI+4xyRqQB/dHFXZ/i3qzXKfZrW3S0XGYXQEHjtTvboFk+pwUGlX7vhbG4Zj0Hln/CnnQdU80IbC6Vj0BjNdy/xd1ghxDbWkbkcOE+7UMHxX8Qru87yJGIwpCDK+9DlbZAoxvuchF4c1V7lYvsFyXIyF8s5ph0PUE35sbgFOuUPFdXL8T/ABNI0TGeFQrZyiDLD0zVqX4reI5dwjS0Clw3MWePQ1N77oGop/EcU2gamIRL9huNvUnYcYpYNC1O4RmSwnZegIQ8V103xY8TSSMU+yLGD9zyweKkn+LfiKQKLRLaEAc/uxzTv5fkHLHucZFoWqMRELC4Ln/YPFJNoWpQMFlsbjJ7bDXXW/xa8Sosgk+ytIRgERgYNS2nxd19Jv8AS4be4TGPuDINPm7L8gaj3OSt/Der3Fu08dhcNEg+Y7DxUKaFqk27yrC4JHUbDxXYy/GDxAZGMccKRYwqhAOfWg/GHXvsvlrbwJP3kVBzScn1QKMXqpHOHwbr6w+a2k3ITbn7lUk8PayR/wAgu6ye+w1vXPxQ8WSTF0v1RTj5AoxVz/hcHifylVvs4PAztHNDlZbfkHLF9TlrLw1rN5qK2cWnXH2hhuAZSM4qNvD2sLetaPplz9qGTs2Ht3rsb74tazdaK1nsSG+bg3UYAKj2qe0+MOr2ulwxzW0U95HgG4IyWUf1oi+ZXSG4x7nnz6dqCFlewuVb/cNRjTtQaHeNOuWHQkRmvSZvjRqkkhMOl22wqPvAZJ71Bc/GLWXEYtrK2iVTlhsGDVX7L8hWXVnny6VqMhA/s263DnHlnkUx9PvdzK2n3W8HkbDXpV78Z9UliCWdhbxXG3DMVBpkPxk1VYAs2mWsk38Umwc1Cnrs/wAAsmtGjzhNMv5ZNsdhdGTqF8s81aj8Pa3cRs0Oj3ZCct8h4rvj8Z9TKN5Gn2iy4wGCjg1Tl+MXiV2iykCBWywRR8w9Kbfkwsk9WcAum6izukWm3bMvLDyzxT5dH1aOJJpdLu1jPfyzzXoJ+NGsNHL5djaxylshgg6elV3+MniEXkMksVuYU+9HsGGpc9ujBJPqecSxSx7lmjeN+pVhggU7BZ1KjjpmtPxJrU2u63c30qLG8+CVAwAPSsoMw6kkZxWrZLvc5PX1b+2LrC8bv6Cil1vzzqtwRnG7t9KK74yjZGV2bLk7mpdwjA3Yw1aup6U8PiHVbKxikuUtpiqBRk7ME5NekfCjwnp2reHJr7ULVbiSWf7OdxwIh6j3ribS1NuVs4v4c20N74x0q3nhWaGV9ro3Qiu5+LPhHS9HuNuj2uxyWdzngLxWV8ONDVPihdW9pOkcWnzsE8w4LqM9Peui8WaRq+v3LFtasIVV5FYF+SpxgVm5PmaZTh7uiPGwysVI6YpRlz8o5/nXd/8ACtbkYH9u6YqgdN4pyfDi6U/JrmnN9HqtLbis+xxdnZS30pW1hZmRdzDHb1quCWGcEA9/SvW9A8Maho1yZY9T06RJE2PjnIqlc+BjJrrXp1fSxbMebcN0qW1ewKMuxynhDwvdeKbp4bHCJCN0rH0rvfGvw403w54NuL8StJNGoIJPRvStXR9Mn0eSZ7O/sIopwAccZAq7rjXeq6FqGmvqenvFcryeuxvWkpNS12HyNo8Th024n083KDKADp61QyNuV5GcA166+gMmiW+nQarpcaJHtZ8/eb1zXMr8OZFBC+INLznj5s/1oUkSoPsccq/KN3J6e1dp8N/DVtr+leIXuVBntocwP/dPrSf8K+n3ADxDpRI68/8A167LwBp03ha21CCTVtKnju1xyeh/Oi63uUoPax53q/hS/wBJeC3ljMxeHzGYdutdl8KPCNjqdnfTeILUSqEBh3DkD1rqp2F1pvkXl3pBn27d+TkDtjms/QY9S0slRrmkGPJ2pz930PNT7TS6F7Np6o8q8Q6cum65fxxhfJR8IqdAKz47WaRVMSF9xOcdq77VvBt3f3s051/RkV33Abjx+tSad4QlsiMa9oxU8H5zz+tU5KxPI77HBfYrpomb7O+1TzgdK0/C+g3GrXQeOEvaoMyMRwK9IvdOnmCC01XRIUClWw2d1XtJ0260i0TyrzSkt5TydxAdu9S5FKLRgfD3wwf7Yvbq6gBgQN5IYZBX3rzaeJY7u4UcETSDH417v4RF3b6kYG1HTZreRGHlxyZcd+K88uPBfn3l1Kde0gCWZmA877vPT601Jcv/AAQcJPZHCxsgRwcqR3r1jwX4Eh1j4erdSQK+oTTbo5A3JQHoa59vAIcOv9t6SxI/5713miSahpWhw6ZbanpflxIVDC4A5PfpSlNbXHGm9boba/C2wk1JJzk2igbogeh7iurvvAPh6axkht9PjjlK7Q4Y5Wsy31e/tbGONb3TDICPMkNwPmNR2es6la/aRc6jpcjyvkYnA2r6Uo1LD5Oh474h8NPper6hajBW3wVJ43j2rGs7OW+K29tGz3DHCqoya9U8X+HpvEmqRXi6pp9v5a8qsuSfrVfwx4ek8Oakb1NS06SUjCl5OnqarmW5nyO+pzer/DzWdNtbeUWxk3LvbbztHvXL3Fo8CRMww7NtZfSvbLzUdTmedo9Y09FddgUzAgCuQuvCbXRuWl1XTvMnJIbzRhT7UuZDcH2OPstGknW4CwvLN5ZdFHaql5ol5aaSl7PFiMHH1Nei6dod/YyJLHrWml1QR5Eg5FX49GuWs/s13eWM0JlMrDfxtPYU+dPcORnkFlCbqQKATu9BV/8A4RjUptLmvViJjhfHvmvR/DPh4aTc3kwn0+4ec/uhvB2Vq6Fps+jS3gury2lS5k8zyS/C/hRzJLQOR3PMNc8OTWv9lP5YgNzFlkJ7+tYN9B9kuJYXPEZAz65r3rxFHa6olok7WcbQ8As+OPQVy8fhS0kuvPv7zT5i0m8qJB07D8sU000NxdzyWNQflU59vSlI/dkgZxXqeseELG6kY2V3YWxJBB8wc1XXwTB5FwpvtP3sPkIkHy+tHMloyeR9EY+q6BaQ/DLTdUiGbya4AeQd19K5yz0i4v8Ab9lwAJBuYnoPSvatCt9P0zRItMvnsri0jcSIC+QD3q5ZwaFalxFDYpG+S2JOualT0SZcoPdHM+L/AANpNvpOl3lhaMjzxYcKc5fHWvIJ4ZBczxoh/dnbj0Ne5a6dV1CEwWGoWMFtGu2AF8hfeuF/4QHUPPkkGuabvY7mJcfMafNdasTjrojgkhdlD7Mp936mlS1lnZRbRO4Y4xjpXcJ4C1NXQx61pZCHcF39TXSW2g6pBOsqTaeAIypwOr9jT5mv+HFys8e2ukrrIMNGdpU9qacE8jr1rV8R20sGtXsd5JG0+V3sn3Sfass4JBPQfrVO1yVe5zGsmT+059rHGR29hRSazLt1OdRng+nsKK6Yp8q0M2tdjsfD3ivU9C1W51K38ua6uUZJTIM53DBNXvDHjjVvDlrPa6f5LQTkuUcfdcn7w/OuTQkjPGR1BpxHy8isZJWsb8zudz8N7mW++ImnzXDbpmkLOR3Jqtr+owDVriMx7ZBeTfOp4AyOv50fCdmPj7SVUcFuTWNr4I1zUhjGLubn15FRGKleS6DmrRRsHTbHylnkuX8xvufNw3tWyulafYTS3UFyfNWEKYmbI3HvXBCR/JEW8sFOVz2q9LqTPIGUcbQPfIpe8zO6R6t4c1LT10SeECN/JQlCw5Zsc1y6aKunz3eozGRrcSCYKT94N1/CuV0PUzaXqSSfNFk719c111p4ijuNPjtZPmUO25j2XPC1Pw6FXvsdJF4ngvdO+zrYxiKMgxy4/h9DXVeBBpWpWlz5FiqPtbzlPXdjrXl+vXcNra2x0+PZbysElz/e9BW18JNenj8Sz26RmSO7cBsD7nNS9EmNWvZhb6fp3/CPT28rNJJJduinoVJPArmY/D8ltZ2k11vMc7NGmDyjA45r1DxJ4bllubpLZFVEnMqheOfWsnQ4bjUNSvdPt/3pG1hvHCZ7Vcm7Ba7sZ2hfDr7V5BuppOF3tg/e56CtPxdoel6Jp9xpfMpSF50kJ+dPlOBXpfhjTZbW9zc4ZIowB/sk9R+leQ/EGVJvGXiGLzwVSxxuzkAntTTHbQ4RtXle3tC4X91CE4/iOetaq+KZFKTGCMzKQuQOqgYrl9/7tNqkDAxmhj+8Xqee3IrPyJuzrvD97bXtzNFeqrQSszFPT0wa9Aj0/R/+EeDPGEkSFmOezZIH8q8XVjDIDGfmHIxVxdVvNjx+e5R8ZBNU7piueqeENTsYdCt7uREmlSZ1K7c5XsTXqP2u0mlsrJrdG+0RhyNv3BXzR4Vvfs1+sMkhS2kbLkc9/SvfbFbiTUjctccPCMMF4MeBgj8qlNrQ1VmiC8jtofEsS2/lDbJsMRABA+teD3EaXE98+7EzXciKo4AG7pXvmp2St4kju/LKxuoeE9Du964Dw74ZsZmQ7w7xXbzTv/dYsflq000yZJ6Gd4d8JRXXi+wtZY2m0+VcsynkEetejXNvoNtLqBubGGGCIrbjK8s3ODW34dtoLCS7km2i6jBZiF4AJ4xXjepaqbzQ/EiGZpiNRR0kbgkA9BUu9r3CKRvfEs6No2gi0sIoWv5GDr8gOOa8+udThuPtMgt4VkdkCHaMDFV9e1CTUdWuJJWLfMAvsAKzDkAYHTqfWhkXue+/DVNH1S2MMtpatdiErIAo6Vq654W0RoE862hWCFxyFA/CvnvTdVvdKuhcafctHIBg46EehroF8famtrdwXDmdZgAob+E96LtKxTafQdq/hOyS8uZrcj7NJKfLVecLWLqem2dukaA5fkufb2qx/bpXSpYVfFzsYJ757fzrFklef77k7FPB/WqXvIlobdxwKwjjXiMhsg/ervdH1e2vrWxF3aw7yvkybeMoOv44rz5RkA4wD3NP86ZSoVyoB3LT5VuhXtoe2aRpHh6zDX1rF5kITzolY52kdveuf1jV47vULrUhp0RSFQkaLxnvmud8J646Qm0uSWjIKjB6ZpdU1uLS57pbVlufOQRH0Qj/AOtUJtuxXodt4ksNP1bw/patAsc9xH54ZcjaR2rzqfw9EHuGZnikjTzNhJr0gldb+H2n31sxUwSBCRwc9x9K4u/tJ59YllM26IqVk556cCnG7Vxz0ZxlzbrDudWdo9wCtu65q3pumC7mCtK6ggktuPFSRWTlLlrhSkULmOOL1YdKvBRaWaXAQgMGSUf3CRx/Wq3ZFyzfWdqvwusLlWczNqnlB88sgrl9xDSLukGWP8Xap2ml/wCEWt7V5D5cVwp2noD61QclW+XJNCdinZm7p2tvZ2K2RjEsatv3k5I9qptLb3FyhnkdYzuICtjk4qg0vysqjajHk96b0QZUEqQR7UOz2DqdFp0FjpmoJ9olkmj2b4pCerV7f4O8SWGq+DH1W5itvPt22OMAD2FfOD3Ej+Xlvlizt9s9atafdGPTb6ylneK3mXJVDjLDkUnHVSQ1Kydy54z1GLU/EWo3UMaRRuy7VXpwaxVEbY5ORyRUSgoqZB27R16561IeX4xn27VT73JWxzeqn/iYTYUkZ9Pail1R3GoTgYA3dMUV1xbstDnd77mh2NGD1yfpQnIGcZxT1IIBJGOmaxsdB2PwoSV/HuktFE7hXBYqMhR6msLX3/4n2pjJ3C8nH6iul+D+o3Fl41sYraQLHckRycfeUnoK5jXeNd1RCc4vJcH2zUNqLaHJtpFJFO4licdqeFAA570hB3jB46Gn/KQoIxxUJ20DlSFKgyfL0HNSuJIwI92OQ+KiOQvB9wKezFtsjHJHBz3o0C1i9quoPfPCqZEaIAUHTf0z+VdX8J9QNprUixACaYpGjHt8wzXDBsMQvHoa0NGvn026SRMBt4IJPTkVLi3GwuqPpvxVp12TLcWDZCMG6+wyKb4d0fyL9L62RUMqo02P4h0/Sty2uLe/0+3MTbxMsZbZ9O9XbhorO0eZ4yqAYYL2HakrbmnKY/iPUV0zRru5Vl8qMNknrntXyvNeS3c95dSEtJcFpCSexr1n446sqWdta2szr9rUP5XYjua8cJwG8tsqBjHtVJXJm3ewgYEbc8kdPSn5C5bB6dRTOS+c5x933pysWxuPB4xS2J9B6yE8NwPSkViG4Bye9JgjNKvA9qpsnqOR2QbkwG4r3h/FC6PceGbJ08x76zTb/s4J4rwR2OCFBPauj1XXTqd1oUmxo20+2MJIPPXgis31NYvQ+jfEG1tU07MZZyzKCDgKao+GNAiht5TboqR3GXkOAcuGPIqxoU0GsaRot/FvnVYwFkbqWxhi361v6cqW1iiqoQc4z65NC97Upq2hz3irURofhW7uhGm5Q6Lvb7xOcV87wwy3HhzUTtJn3rIQv8Tlq9c+NWuWKWdjpk2ZJGnR5AnGFyMnHetDw5qvhV9Kmh8KS2NrfbeGvF5DerE1TtdK4KLkzzbRvhtrusRzTNF9lQ/MrT/LmuL1C2a1v7q3kKloXMbEHgkV9RaLFqx8NTR6/Ml7esWLNZnaHXsF9K8dudd8DWNxLDN4b1AzxyFZN78hu+auVkTOkoyaTPN3PzAgY7mkyC3Ixu7Vo+IZ7K71OW40q2e2smUFYnOSD61nKMj7wz39qTfYz2Ax7c5+oPrTT8o4IJpXDkDOST0FJwPrjtRe+gIMnOO3Whsnlvwpu/cxHXjn2NLk4AP1oAlti0UolV9pwSCDUCAEZOcSEkn39aUYJ/2cUAevY8ClHULWPXvAkk914OuNKhwfKj86Nh2O4cH8CaTVdNZGDafGHkMW64+g71F8CbtpNX1OGRhs+z4RMdeRzXf61YwWl2J7eZbZXjZG39GB7frU3toaNXseFXN19m1kpPG8sbId/s+eoqDxPfsB/Z6piB1UyserNnj+ld/qWk29jeXtzNEDIj+coPQIT0/HNeY67IZLny3O+Yt5zewJIA/AAVUVfVEPQpsWeHY5+XO/HvULgABQTkHg+tISGQEdDyaVlAfDHJBBp21uFxjFkRt6j8aecY64JHNADSDLcgd6jYkbt3r+lN76AmIxCZGCemKXcSOVHzfpSh/lIcfMabkscEEYOOfSmtRb7i545yAOM03OcYBHPJ9aU5J2n7u6nHlSoIyuCBU6LUexzmqBTfzZHfv9KKdqap9um3rls8n8KK7oSfKjFnp914BjuPHV7pllP5ejwIlzLcvx5UTDOPrW54esPC/ibxrNaR2jR2sFt5VpAOPN2/8ALRvc15e2sak6XCveSlblVSYZ5kC/dB9uKbY317ZTefY3LQTFSPMTrjuK5mtNXqbtq+mx3XhrSzo/xZtbFgq+TdBVCnICk5X9K5TXlQ69qQX/AJ+5hn1+atT4dTyz+PtFe5laSR51YsxySSw5rJ8SbTrt/tPS6lHHpurPmu7jdlFMqH6YIJB/Om4LHk45/OkdSJMFt2Rn/wCtTlJB2jofWhvQXoCqCQcnHTHpTjuB5A44oK5c7OAeMUqAjdk4I7etCVx6bg2ChIPPHFPAUxgsMk9abtCp6k8ZpU3FTlcgc0WE9UfTvw0vrebQoltHXesCudx65yMfpWnrespa3NqJpCbWVCjL61458K9RN072UreVCtuyKQcHzD0NR+JvEEj6xFLLOfsyW0YCg8I2AC31NZRT2RTZznjnVH1TxASXylvmCMZ7Zrnt23cOducmh2Ms7s7Z+csPUjNIp+djj5Tjj3q9kZvUXcAfmOPTHcU9O24bSM4pEYgjocjGR6UruXEajBCAjNNWQkKXB47g4xQTxlQevSoySXzxnocdjTmBKDDYNLfcB4JwcYNPRiuOmfeoo8cgZ64Ap4JHHU5waEOx9DfDnW/tvw8CWrus9jGwZ9vAO7gD8K6Pxfqq2VtDG9xHCZELDecDIA79uteY/BXVC0k2l3E6Lbk744G6yEjafyzn8KvfGS8lga3jngjm8+2kgSQMMJJkYIH0FRFbpm0pJxTPNfGOsT6zrsl3Lj5EWDjn7p6j2461k5/4l906jkbc/nUT5yQeQMKOfSrMWz+yNSjc4f5Sue5zVRRle+pe03xNrekuTp+pXEY6YZtw/I1l3V1Nc3UtzcP5s8r73Y9yepqJsiQnvyKUDHAwAaIxXQG21qIW4IJOSf0pZsArgZJXJPpS5IJOB7UwnkgdOoFN6aCAHJyT7AE9KXJUkZznHNDABl4yen0oUcAkHBNJiQhX58Dke1BPAwecc0EcgA880x0By2T0xTvdjH7sZGOQetMjBBbooz+dKvykkH/61IFCgD09aV9QZ6D8Hb6Ky8Q3rTcKbVtr9xjBNew6vLZy2iPqKiXzArQr6ZUEfzr5w8O6nJpmsW88aq2WEbBum08V7vquooLAMqI7EIeewxtOPwAqJbsuLvE5Px3qFqI5AHcSKg80HvGpGAPrXk13KLm488AhpCSfYdh+WK7nxVqMF5pjyPtN0LJY1Tvv3Akn3wDXC3LiRgVXaNoyvv61pGyRMnqRzMpOUTA4x78VG4wme5NSldrEdVIBFRFM/KOR1zR5kphg+mOeRSBD/F16ClZ9rNu+6MEUAtvJPTnH0o2G7kbqSRwCF70pUbcscnI6dxRuZCg6gelDB+NuMdvai9g1FwdxDf5FBBChujdTQeDk9+poI2n5fu/401ZgjB1PZ9vm4J56/hRUl9Cv2uXMmDnpRXZGdkjJkyjpn2qQL3PHJpicN8wJ9KkA3A5bg8/WueTuaM7T4SXkNp44sEntVnaYhEJ/5ZncPmFYGugNq9+MDd9pk59fmNavwyw3jnRT0PnjH51meIFT+2btg5ANxJgfVzWUfivuaP4FczxuEhO3kY/KhPmfHofzoYMspAOG7H2oBOCQc/w/SrduhmpCxDkt0GcZ96kXgL3bnOabtO3YejdfbFSSKWCtgqpUKPwNT6Dv3Ez8xwDyRxSrIxXaMKDx06008uxBxk4FSoo5OMdjRsK6Zd0fVLjSnuniwJDHtBHTNVpZmm+SRtw2qPrtGBTWXIco3C84PcelNJAAweMZ5qebqFwYDIwOc80ycmKJ3jXeUXOB1JAqQHH4ClAOCV9CSaaemomyCxkeaBHkXY7dRUwwOSMHnihV+6obA/lTh0J/p1qRtiYI7DOf0pQDvzwSOOlKGKR+WRnnOep6UoGQNvLDkmmriuNHGD3FPjXJJIAXPWmg5U4PenJ8o46e1VHzBM73wLZ3mg6zpOs3Fms9tdAxwKj7nJZTyBVXx/p9550GoDedOf8Adxb5N7FyW3fT0qP4bxJe+M9NguiZIFDMEY8BghII/KuYuZGadw7sW3vjJzj52qai11RV1ayI1BPbOaswhRp2oMAMgLj1wT2/KquWB4G3HcdasxqDo+oy5IMZQBexzmlcRVYbScZ5HHFP+VkUgFnyQRUSkFcjrjIzVqwUyzu7nhULAepFFxNshJ+QYOT6HrTQo3cryDSxybwGKhT94+xJ6U/fgHAwT+NFwuNbpwfr9aUbcjIwF4+tR4LHO4AEYxTxhgdvAB5/xoC41iMDA7mnbG8lnByM4/HFIFA5HTsD3p4BEjRg/ITu9s4oWgOViLhW46gfmaRwuPmGM5zTs4Unnf0owcc4OBz7UaXEvMjCEhh0OOK7Q6y6eH4JzKxlPlwMD25I4/DFcYVOMnoTkGp2u5pLeCBguyHIX3JPU0WT1KUuVEl9OLm6eVQRIxJfP949apE8YJHFOCktk/xZJNIcZBP5U7Et6gw65pASpHYChgQpODz1P9KTpy3fmm9RiN13HoBihuflAH/1qkjQM20c8EnJphHPWk9FcExq4X+HjtQWVMljjNLgjB9aQruHzcg44oTuAxMAc84JOKRd2dmOM84qUKQmAeKjAYBQByOSfemnYdzKv4A93IxbGT60VPdxk3DnPeiumL0Wpk0RqGznPzZ61IisykIkjjqdq5rVsNFvtS1ZtOtLVnvEjLtH0KgDnP0r0b4SXkdlp01nJo32xrm/8n7Rs3eUSAMH2rGWiuarV2Zx/wALRnx7oYPXzuARjFZmtAjV7slc/v5CF9t7V2/gvT7eP4vtb304ikt7uQxMg+WZw2CB7d65TULSa71u9jtUaaVWlkKqOdodsn8Kii+VsubtT1MLny8MCCe5605wm8MvG5cZ9xVm4s7i3jt2uomjWYB42PR19RUMoVmOOApxkfrWjkmrowWggINuwZsEsFz7VMVkeNiwzGgHTtVedkVtmQF24z71NFLtjkSN9wYhW9/aobvsUhgIbIb5VHT3FPyxyFHAOD70mwmQtjJ7A9KVgSSo+pPtS1K6jtqhxjgYOaVlBySBtx096RTjBwADTmIUFicClurCYgAznoe/vTsZUKMnByce1MVopFJ3ZccD+taGlq5h1NlUEC3GT/d+brRGy0Eyi2AR60m7G0AZJ6UqAnaBySwVf9ontVi5tJ7W4eC7ieCZOGVhytEfIGRkMys5XhjtB96QrhA3HpUsMU08kVrbxvK7PhFUcs1XJ9Hv7XUWsrqzmjuW4SIjJYnpgiizEUNoALMMDsPWnrkqdvUc49atalpt7pV0kGpW0kEgUHY/p6/SqsRyeGByM5H8qa03C51vwvyfHenHP8Eh6/8ATJq5a8BF1KrYOGb/ANDaup+F6OPG+mMUbYVlBYDgfumyPrXM3YU305JHLNgZ/wBpqeIkpR90OiZAN4UccHgE1atkzo16RkgSxqyj/gXJquS21EBLY5ArX0S0uLvQr6C0gaSaa4iVAozuPzcVjFNFO0jBjZQh7bCR+Gav6ROlvaXW9QZ2j2R5HT1P5VPqHh6+sb9La7tJop5gNkbIcvk46VLJ4d1i3v7OxuLaRbq7B2R7SDge1Va2xNvIyPLOVQAlhx9QelDKyv8AMQD0IHbFamr6RqGk3wj1C3lglYAISOG7cUybRr5NTi0+SCRLycjZGwILZp2aCzM3su37zcZNB4AyPmJzitTWNE1LSJEiv7Z4XbkZGN2KzyG9O/X0pNW3BsjQncM8AZ/CpMmKI9CD82fXtSKuH+hPNOli3IJASyjovoD2p2vohXXUbP8AKWAHJHX2qIEnB6Z4NWZXMkaMwbIjCA46kVAyBVDZBHQ49KVhp2EYMQoXIUdAe3rTDwR6+3rUjRnA556j3psilGJJ4HJPpTTsAgIIwxxxgfhTccjmrU1lNDFbyzQusU6+ZEWGN6+oqOKLczIAfMY7UH94+lEhLQbuO3aRkFi5HvimHkHjAPat+/8ADeo6docd3qVu9vmfylyPvDaTn9KwnTYN+QflyfansN76ilNkYc/xHC1GqnaMdWzWxpemm4u7WB1d/PgeWNB1ZtpwB9TiqDWlxDGk8sLLHuKb+24dR9RU3uPUrcZGegHSm9gTyacvzIGzk+npTpgirGV5JHP1ptsSGOdoxnmmkYBPr1pTjIJ69BSsO6+lL0K6FGeJ2lYgcUU+6yJ2wXHT7vTpRXRF6Iwe5NBrep22pPqUF20d/JvDzLwSGGG/nU2k+ItX0tpm02+e381cOOxPr9ayQN24+nApUA2Z6jNQ1d3Oi7ta51Xw5uppPiLoLzP5hExyznqdpyc12ELaf4X+IMU/2uK5hvA9pOVPCJKx3Z9wQK8qt5ZYZFmhYpKpypU4Kmuk8B6Zaa54na01Fzsmt5TEc8vOACv65rFpxnzXLpNL3bHp23SL34g6bojeVJp2lWL2q724Z8E8n2NUfFfh/RT420FtOltra0mhFxcAsCmVONv45/SsTUtCsvD2seF11ESyXN1Ev9oRq3zCR2AB/XNO8Yw6Bpvj63037JcNYwyLbSqXOWckYI9hmrnPq3oO13tqaGqaTo8Xxa+xWMVtJpzQmSdSwKIpQFiPcZJrG+JunaXp99Z2+jJD9iW3VopEbJde5b3zVX4jQ6VY+IZrHRIpoDb5ikdmJMhzgn8uK4+RnTaDvcDAAJ6DtiotPnv0E3G1tmTcCQZ7DIpVB8qVhgZABz3FMHBG7qTwKUlWyO+cGtVuZa2FVQpwMkYxj0rX8KXNjaeIrK41UbrJS3mLjPY4rHVMNkGtDQtJbW9at9Lgcxy3AOH64wKTaS1BXurHR/EPVNB1K8tX0GLZGseHG3Hzc1k+GFiZPEHm3CwothkBv+WjbuFFWvGPgy68KT20V1cicyx+ZnAGKq+ENFGteJbSxmLCJ0eV1XqwUE7fxxioknuVf3rDfBnmDxLpht0t2uFbIWc/J1GST64rtfiJo63Pi69aW6tc6g8X2V43yBuwhLVl/EXw7Y6M2m3WkxeVHdxb/KVt21gcHB71zmlWX2/WLO1ubk2kBb55pf4QOcY9T2pQbV7FP+Vo67w/Y2ejfFRYJruH7HAHtxMG+XJQ85/rXW6xNbweKvCnmXcEZtYZVlYOH652ZPckYrjbzR9HtPihNpd0zrpULHeOWYYHXjmtXXvD2iXPifw/b6WM6deo8rTxMW8zZ/Dg9OmKTS5nrr/ww6aklZI3NYj0648T+Fraf7MTbxTNLCZfMUA8qC3fNUfHmhaZc+IfD8Wk/ZYWu4nE5VhtRRzuPvzWf4k8Iwya1oMOl7bRtQR8hZPMSPb3Dd81zfjPwre+GZrQXFysyzqSkik9M8j1/wD105NpaCk/5kdtompaRY+I9D0bTGQWNvJIXuH6zOY2BYn0rH+LdjYQapDPZS2g3RAPFCPuHJ5P1rztQQ6nJ9zS8sdxG73rRyUo+RNSaasOJBkXpuGRx2GK9H+EN5aw28iXMscUwvhIgY4YgRvnFeZFTnAJBFbvguwi1PxZpVrc5MErMHCnB6HvWU7uOgqbakjs4/GFpf8AjDQAI2t7Kylf95M+9iX9TjpzXVxC1tH8Mrd38cmq28kskjySBm2FWO3/AArktd8EadENAsdNuBJPfyzK05OR8ucD8OlZN14Lk0zxrpOlXtyrRXbb1nT+6FJ4/LH41nBezfM2bqclpY7zWL2wv/EXhQw+XLpnmSTbpn3EN1Ib8elYvjHU9P1aDwve2d2WvBfEeeVCuFVxkH2AzVOTR9J1DxF4dS3tbuxtLiaSOZXbO7aeGU9s1Z8Y+CbJ9T0Kxs1ewvL6Ro3ikk3BVBzv/ECtqknP4OxKUovVdSb4qzA6TZwvdpcXKTTzffDEI2Nv8jXlDYZlyeT1r0Xxf4RstKvtCurMTmyuLoW0sMv3zt4Zh7HqKb8R9D0mzgiudLt5YClzJayK5znYT8w+uKPdW+5FSLk7nnkeN8TPkKrZIPerVjcwwajazSf8eqTCSVD/AHc1WkVcrySKlsrQ3moWtqhCmeQR5xwPei1lqZJe8rHa+NfEvh7VbCCDRLeJJFDl2VMemP61wMmFAIGW2ggdua7Txl4Gbwxa2kzXsU/2gsMKPu4x/jXEy4ZeMcDNF3YqV29UW75YUisjFIHDQBnA/hb0pulvaLf2h1HJsxKpnUfxJnkVUEZ24BAPep7eA3NzFbCRI0mYKZW6Rg9zS13J5tdD0j4o32k6no/hifSnVIGgKxxj/lnGXUDNcprOkXHhfxNbwxXEN3cwPHJG45TceRn6Aip/iDodnomsQ2VnNJJAbWNxk8EsM8e1Yul2v2zV7K1u5niillVZZXzlAeM/pRGXN8fY1er0Wp69eizltNG0e+1VL6eDUy10zMDufy2LKPbPFM8d+H9BXUfDDW0UESy6h5VwisMOmM4NYvinwbZ/Z9Ju9JaSGe6ujaZLZ3nk+b+QNY/iLwTrWk3Wmx3V61x9vn8mJ8/6t/X8qaTTs9rf5lN943Z3/i2x0ldX8GXNi8FtNHdLENrABU+9z+PFc3r134fu9D08W8PlWB1mYXa7vm7ZYexOKx9R8DalpOtaDDqt21zY3dyImdGOVAPb8OaXX/BVxpujQ4Aa8utRkhgQNkMnGD9f8Kzd1Ube1v8AM0g/den9aE/xW0rT7B9NmsYFge5gLuqj+HcVX9MV56zKrKwA6dK6bxpo2saVPANXu/tIliHluemBwR+FcmEYH5hk/pW3Ps2c0o6uyBtpIK9KYQVHWndBjsO1McbCSewpPXUWwSbdx4/OipXXDdQOBRVqcrGD32E17wxq2i6jBYXVs32m52iIJyGzxn9ae/hrVbbW00ea1YagTxGRwff6c17Je6tpI8a6CrXcMotrGYzMG3KrEZAB9fSs/VvE+kXfiDwzqEE5RWsp7WSWT76Mxwu78qfvW5raHdKEV1PNLrwdrdrq5057b/ShbtcgKchoxySKil03VfD1zp19cxPbyZS6gPfAPBP616Fo3k6B460s3mupqKQae5kO7IVcZEefcVjfFG5GpanDfW9+lxZXcXmRIDzEOmwj2xWUJKreLJklFc8TNu9W1LxZ4sbUbeDzbqIi9MZ7Rxtn9AMVph9a1Txtaav/AGXHLcXiNdwxP9xlGPm/DFZnwxvrax8UTy306wQzWMtornszAgZ9ua720nt9H8SeH7U6hDcJp+kzRzOp+UkkHb+tXyqWg4WetzkPiXe6hdauh1bTYLK78vcWi+7NnndnvXFy7hgnABxXR+OvFb+JLi1ElusEFqnlRIvJC+9cyGDIN3O09PWs22mZpczuPJLMwOCcdfShQAgHHqaMkSMF44zg+tIp+bBPI6cdfaqS6gPRmyQ55PIxU1pcTWs8c9rI0cyZxIOo7VXLsxDADGcYNOYlV4HAPb0ocWK66F++1O91Bw9/dSXDqoUbznAFSaFrF1ouswajZkCWHIGfQjBH5VlscksARjinKPl2sRu65qZR0sCbbudb4g8aXOrarpd2YI44tPdXiiA+XA65+uaq3viV7nxV/bL20OPMMhg2/IfQY9q5objjJG3+dPY4HOfwojGw3Nvc7bV/Hk+oa3Z6stjaRXkSMrsqf6wHGd3r0qG88d3s+o6ddWttb2wsVZIo41woDfe/OuQH3Rjp70ZPKg4pTipaAuZO9zuZfH13Jq+mXf2WCOOyRo44UXCkNyar+L/GM3idLVJoEiW3QqCPc5rkAOvSkzzjNXH3VrqOUnJaku7Mh4xnqPWhWZmJz161FnjgUoPXGP8ACjmuRYfvwSMYHfjmtLQNXfR9Ytb+ONXeDIVT0OQRWU5Oc8nJoB7+o4zUN2Q1psdPaeLLi0XTPLjDCwkmkQnuZCc5/Orq+IdR17WNEWyhA1KFRHD3BwDn9Ca4sdCOOexrd8G3EVj4t0a5ncwxpKQ7egKmplG6uXGbTt3PQNVm8SR+I/D8ctlbJNH5gtbeNwQ5x85PpWXJqmtvceHdQurVWuI7iSO3ndseZgEbW+ma1b5rNPH3h2/iubFIVeTJtpzJsGOrZJxmsr4g61BqvgyxFtCsVxFcTboo25X5xyKe1r7Gj16lrxFH4mibQtO1KITXJu2mtyZAWZjzj6dKZ41/4SPULjTLHUbS1hkunZYVhfPmOTlmPv1pus6nat8Q9AvzcHyIFiDybyQv7sDH51e8QS2yeLfDmowXVoqCdseVMX2/KeTzxmmoqb100JUeXr1OG8R+GtU0DyRqESqJs7GU5HHUfWsaN5YpFkTKPGdyt3B9a9J+KWuWGp6NZHTGT7IrvuiLZdJM/M3PY8V5jvEi4wcnofWqk7NRMm05aFu91LULuFVvLyW52ZwGP3c1SZiGJxxjpQ7FiegAxyO9NIIzzx6+tJNi3JE6kt97096lgdI5YXKBljcM0Z/jHcGqZ3Bj6U8HrwcGmnbRg0df4h8T3PjI6dpw0yGK93KkLp1bbyq/kDUPiO/vfE/iBLdLGO2v5iII44xjLIMEfoay/DEyweKNCuHk2JFcqWY/wjaa6bxVYS+HNag8Q2uqWtztujNFHEwLKM5OfrmpnFwu1uaRk2rvuWL/AF3WZF0a7i08pp1jMbaGNed020q349a2PGniLWpJNAF/pwttl2Jrd88O2MbT6VY13xDpenal4ZWzdUsYrkX92BzhnGf61Q+IV5bx+EBAt/Hd3El1LdxBWyY0Yjb9D1q4NTstl/X9fM1l7qbuT+L9b8QWcWiTapp8UJtLkXMZ3Z3nHP4Yrj5PEmoaokOmW4ka+k1B7u2JP3S2PlH4A1c+JV8t02jeXdNOFsIgTuzhtoyD71yum3zWGoWd8gzLaSpKuO+P/rGnTjKcbW9Lmc5vmszuvHWoT+I7PTBaWZjghY2ayyHrMD8wP45rltY8I65pn2QX8CRNdvsi+fqf8K6v4s6zY/8ACOQ2GiMuJA1+5U8iVxn8+azPHdw1/Lodul8TK9pDErluI3xkk/lU+ySlq9LDbUrmFrnhbWdCjil1a3jiSY7UIbJNYkiER/OOa9N+LVufsGl3UeqwXixwJblEbJDBRk15g6lkyWyBSukk1qZS92VuhbZ5M/dHQdqKjLsMAAEYHWitFzW2Zzu19zjdI1dyBG0ec5bO85qDVr6Y3qoGZVbqA1FFehCTVFx8z3Mcl7JadCut1KrNh34P945NWYb6d2Ee9gpOOvQUUVzwSSbSPJiSrPIZ9u9sH3rT0tpPtWGmkYEZ5b9KKKJTajoVbQ0nRGIJU889acsSbl69M9aKK5ZdxJ6WEYISRtOR33U+NUIBKnJJ/iooo3LSVh8aJ5m0BgMY60iAMHU7uvXNFFJyaEtRxVCYl2sAevzU14Y8hcH160UUm2RJ20RJ5KcKM4z60pjAbqaKKSbsDdmh32dcZLMTjNOFuGVn3EECiijpcE2HkDcDuOaiI5PtRRVxWo76sRTuTd04puODkk0UVM9GhrYaZsZG3ofWopLnYfu5/GiirtowIzesGI2D86Q37KvCDr60UVm21sIt6Zrk+lzPLaRRCScbGLjcB9BUlzr97O+ZPKyf7qYoorSlTixym+WxE+qSOdjIuD6GqrX3llNsSgueTk0UVbirkdR/2zzCS0fzdCQ3WlF7lR+6H50UVMl1HFaCi+4/1Q5x/FQL0HI8ocdPmooq1FWRVtWPS8GceUMHj71L9pBcL5fH+9RRU8qE9xBeDJ/ddP8AapgnRDxGxz6uTRRSavoxpJsmeUKmSpYE9C1KXREzsJJ4OWJoorOOmw90L54JAZSR7t0p4dRyF7Z60UVbk9GHKhDhiN245GeWoOD97eT2JbpRRRJ33FyoAgIRSZCD6uTTjGnAw3H+1RRWUdNhNl2PbsGQT260UUUueXchwjfY/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pulsed wave Doppler signal is obtained from the anteriorly angulated apical four chamber echocardiographic view. The arrow indicates the dashed line positioned by the sonographer to outline the signal. The area under the curve described by the tracing is integrated and expressed as the velocity time integral (VTI). In this example, the value of 16 cm represents an abnormally low value (normal&nbsp;&gt;18 cm).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13601=[""].join("\n");
var outline_f13_18_13601=null;
var title_f13_18_13602="Episcleritis in RA";
var content_f13_18_13602=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Episcleritis in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Episcleritis in a patient with rheumatoid arthritis characterized by a patch of intense injection without scleral edema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M Reza Dana, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13602=[""].join("\n");
var outline_f13_18_13602=null;
var title_f13_18_13603="Tetracaine (ophthalmic): Pediatric drug information";
var content_f13_18_13603=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tetracaine (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?26/45/27347?source=see_link\">",
"    see \"Tetracaine (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/36/17987?source=see_link\">",
"    see \"Tetracaine (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12608998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Altacaine;",
"     </li>",
"     <li>",
"      Tetcaine;",
"     </li>",
"     <li>",
"      TetraVisc&trade;;",
"     </li>",
"     <li>",
"      TetraVisc&trade; FORTE",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9564877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pontocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10536347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Local Anesthetic, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10536424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/45/27347?source=see_link\">",
"      see \"Tetracaine (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Short-term (nonsurgical procedures) anesthesia:",
"     </b>",
"     Instill 1-2 drops just prior to evaluation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Minor surgical procedures:",
"     </b>",
"     Instill 1-2 drops every 5-10 minutes for up to 3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prolonged surgical procedures (such as cataract extraction):",
"     </b>",
"     Instill 1-2 drops every 5-10 minutes for up to 5 doses",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9565238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 0.5% [5 mg/mL] (2 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altacaine: 0.5% [5 mg/mL] (15 mL, 30 mL) [contains chlorobutanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tetcaine: 0.5% [5 mg/mL] (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TetraVisc&trade;: 0.5% [5 mg/mL) (0.6 mL, 5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TetraVisc&trade; FORTE: 0.5% [5 mg/mL] (0.6 mL, 5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9564881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10536464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply drops to conjunctiva of affected eye(s); avoid contact of bottle tip with skin or eye; finger pressure should be applied to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic reactions",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F15848030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at  15��C to 30��C (59��F to 86��F); protect from light; keep container closed tightly",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10536348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local anesthesia for various ophthalmic procedures of short duration (eg, tonometry, gonioscopy), minor ophthalmic surgical procedures (eg, removal of corneal foreign bodies, suture removal), and for various diagnostic purposes (eg, conjunctival scrapings) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9565149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ocular: Allergic corneal reaction (rare), burning (transient), chemosis, conjunctival redness (transient), lacrimation, photophobia, stinging (transient)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10536349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tetracaine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F15848029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some formulations may contain benzalkonium chloride which may be adsorbed by soft contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15848028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity reactions may occur; immediate type allergic corneal reactions, characterized by epithelial keratitis/filament formation, necrotic epithelium sloughing, stromal edema, descemetitis, and iritis, have been reported rarely. May delay wound healing. Prolonged use is not recommended. The anesthetized eye should be protected from irritation, foreign bodies, and rubbing to prevent inadvertent damage.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9565151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9564900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9564901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10536351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both the generation and conduction of sensory, motor, and autonomic nerve fibers by decreasing the neuronal membrane's permeability to sodium, potassium, and other ions, which results in decreasing the rate of depolarization of the nerve membrane",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10536352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action:  Anesthetic effects: Within 30 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 1.5-3 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15848031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; detoxified by plasma esterases to aminobenzoic acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10536465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/36/17987?source=see_link\">",
"      see \"Tetracaine (ophthalmic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical ophthalmic use only; avoid touching tip of applicator to eye, fingers, or other surfaces. Do not use if solution contains crystals, or is cloudy or discolored; avoid touching or rubbing eye until anesthesia has worn off.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16053 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13603=[""].join("\n");
var outline_f13_18_13603=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12608998\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564877\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536347\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536424\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565238\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564881\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536464\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15848030\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536348\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565149\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536349\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15848029\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15848028\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300122\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565151\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564900\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564901\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536351\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536352\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15848031\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536465\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16053\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16053|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/45/27347?source=related_link\">",
"      Tetracaine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/36/17987?source=related_link\">",
"      Tetracaine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24148?source=related_link\">",
"      Tetracaine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/8/38019?source=related_link\">",
"      Tetracaine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/8/43138?source=related_link\">",
"      Tetracaine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/30/29155?source=related_link\">",
"      Tetracaine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/3/25652?source=related_link\">",
"      Tetracaine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/31/2547?source=related_link\">",
"      Tetracaine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_18_13604="Candida placentitis";
var content_f13_18_13604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Low power photomicrograph showing microabscesses on the surface of the umbilical cord in a case of candida placentitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13604=[""].join("\n");
var outline_f13_18_13604=null;
var title_f13_18_13605="Montelukast: Patient drug information";
var content_f13_18_13605=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Montelukast: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     see \"Montelukast: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/26/1446?source=see_link\">",
"     see \"Montelukast: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F197951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Singulair&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F197952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Montelukast;",
"     </li>",
"     <li>",
"      Dom-Montelukast;",
"     </li>",
"     <li>",
"      Dom-Montelukast FC;",
"     </li>",
"     <li>",
"      Jamp-Montelukast;",
"     </li>",
"     <li>",
"      Montelukast Sodium Tablets;",
"     </li>",
"     <li>",
"      Mylan-Montelukast;",
"     </li>",
"     <li>",
"      PMS-Montelukast;",
"     </li>",
"     <li>",
"      PMS-Montelukast FC;",
"     </li>",
"     <li>",
"      Sandoz-Montelukast;",
"     </li>",
"     <li>",
"      Sandoz-Montelukast Granules;",
"     </li>",
"     <li>",
"      Singulair&reg;;",
"     </li>",
"     <li>",
"      Teva-Montelukast",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691447",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used to stop exercise-induced breathing problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat asthma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to montelukast or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696944",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to stop exercise-induced breathing problems if you are already using it for asthma or allergy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor right away if your normal dose does not work as well or if you need to use your inhaler more often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in the way you act.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3516872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any skin change.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695120",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If working out or playing sports causes signs, use at least 2 hours before doing it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take even during sign-free periods.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695152",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is for asthma, take in the evening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695150",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is for allergies, take at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Granules may be taken by mouth or mixed with applesauce, carrots, rice, or ice cream. Do not mix granules in liquids.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699399",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in the original container at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use granules right after opening.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10878 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-0D12DA5E94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13605=[""].join("\n");
var outline_f13_18_13605=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197951\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197952\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027775\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027774\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027779\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027780\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027782\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027777\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027778\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027783\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027784\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=related_link\">",
"      Montelukast: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/26/1446?source=related_link\">",
"      Montelukast: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_18_13606="Alcoholic steatohepatitis - high power";
var content_f13_18_13606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Alcoholic steatohepatitis (high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are several fat-filled hepatocytes, \"hydropically swollen\" hepatocytes, and intracellular hyaline droplets (Mallory bodies - arrow). Scarring (blue) is also seen in the space of Disse.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13606=[""].join("\n");
var outline_f13_18_13606=null;
var title_f13_18_13607="Anom omphalomesenteric duct";
var content_f13_18_13607=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anomalies of the omphalomesenteric duct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Umbilical polyp. B) Meckel's diverticulum. C) Fibrous band. D) Omphalomesenteric duct cyst. E) Patent omphalomesenteric duct. F) Patent omphalomesenteric duct with prolapse.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The American Pediatric Surgical Association. file://www.eapsa.org/.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13607=[""].join("\n");
var outline_f13_18_13607=null;
var title_f13_18_13608="Bisphosphonates and denosumab in patients with metastatic cancer";
var content_f13_18_13608=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bisphosphonates and denosumab in patients with metastatic cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/18/13608/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/18/13608/contributors\">",
"     Robert E Coleman, MD, FRCP, FRCPE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/18/13608/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/18/13608/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/18/13608/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/18/13608/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/18/13608/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal morbidity in patients with cancer includes cancer-treatment induced bone loss and metastases to bone, a common site of cancer recurrence for many types of solid cancers, especially those arising in the lung, breast, and prostate. Bisphosphonates and other systemic agents that inhibit osteoclast activity can prevent, reduce, and delay cancer-related and treatment-related skeletal complications in patients with both early and advanced malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of bone disease in patients treated for metastatic cancer, and the benefits of bisphosphonates and other osteoclast-inhibitors in patients with a variety of tumor types is presented here. The risks of therapy with bone modifying agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BONE DISEASE IN PATIENTS WITH METASTATIC CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with metastatic cancer are at substantial risk for skeletal complications from bone metastases and bone loss (osteoporosis), which is often treatment-related.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bone metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone metastases are associated with substantial morbidity in patients with cancer. Skeletal complications of bone metastases, often referred to as skeletal-related events (SREs), include fracture, skeletal",
"    <span class=\"nowrap\">",
"     instability/loss",
"    </span>",
"    of skeletal integrity, spinal cord compression, the need for surgery or radiation therapy for a symptomatic bone metastasis, and hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SREs are clinical outcomes that can be distinctly measured; therefore, they are often used as endpoints in clinical trials investigating therapies for bone metastases, although not all studies include hypercalcemia. Bone metastases are also associated with pain, particularly with motion, which significantly impacts quality of life (QOL). However, the usual definition of a SRE does not include pain or changes in QOL, which are typically measured as separate outcomes in clinical trials.",
"   </p>",
"   <p>",
"    SREs are common among patients with metastatic bone disease, particularly those with lytic metastases (",
"    <a class=\"graphic graphic_table graphicRef54124 \" href=\"UTD.htm?21/17/21787\">",
"     table 1",
"    </a>",
"    ). As an example, in a review of patients treated for metastatic breast cancer prior to the routine use of bisphosphonates, over 50 percent developed a SRE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/2\">",
"     2",
"    </a>",
"    ]. Other evidence suggests that in the absence of osteoclast inhibition, one SRE occurs on an average of every three to four months in women with lytic bone metastases from breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8042?source=see_link\">",
"     \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bone loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for treatment-related bone loss in cancer patients include chemotherapy-induced premature ovarian failure, the use of aromatase inhibitors for breast cancer, androgen-deprivation therapy for prostate cancer, and glucocorticoid therapy. In addition, as in the general population without cancer, many non-oncologic factors can increase the risk of osteoporosis and an osteoporosis-related fracture include smoking, excess alcohol intake, decreased exercise, low calcium intake, vitamin D deficiency, genetic history, and use of pharmacologic agents such as proton pump inhibitors, anticonvulsants, anticoagulants, and certain antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3929?source=see_link\">",
"     \"Pathogenesis of osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention and treatment of bone loss in women treated for early breast cancer is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37545?source=see_link\">",
"     \"Evaluation and management of aromatase inhibitor-induced bone loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/35/33336?source=see_link\">",
"     \"Overview of the use of osteoclast inhibitors in early breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BISPHOSPHONATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates have become an integral component of cancer treatment in patients who have metastatic bone disease. Bisphosphonates reduce the morbidity of metastatic bone disease, mainly by decreasing the prevalence of SREs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, bisphosphonates are widely used for the prevention and treatment of bone loss (osteoporosis), both treatment-related and non-treatment-related. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37545?source=see_link\">",
"     \"Evaluation and management of aromatase inhibitor-induced bone loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H9#H9\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bisphosphonates are analogs of pyrophosphate, with carbon replacing the central oxygen&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef77918 \" href=\"UTD.htm?15/30/15852\">",
"     figure 1",
"    </a>",
"    ). The side chains from the central carbon, R1 and R2, are what provide the different bisphosphonates their affinity for hydroxyapatite, the principal bone mineral, and their potency. It was previously thought that bisphosphonates arrested bone loss by preventing the dissolution of hydroxyapatite [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/5\">",
"     5",
"    </a>",
"    ]. Instead, bisphosphonates decrease bone resorption and increase mineralization by inhibiting osteoclast activity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31737?source=see_link&amp;anchor=H5#H5\">",
"     \"Mechanisms of bone metastases\", section on 'Osteoclasts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two classes of bisphosphonates, non-nitrogen containing and nitrogen containing, with somewhat different effects in killing osteoclast cells. The nitrogen containing bisphosphonates are more potent osteoclast inhibitors.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     Etidronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/51/38709?source=see_link\">",
"     tiludronate",
"    </a>",
"    are non-nitrogen containing bisphosphonates, and the nitrogen containing bisphosphonates include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Bisphosphonates have a direct apoptotic effect on osteoclasts, affect their differentiation and maturation, and thereby act as potent inhibitors of bone resorption. In preclinical models, the bisphosphonates have also been shown to influence macrophages, gamma delta T cells, osteoblasts, and tumor cells.",
"   </p>",
"   <p>",
"    In addition to their effects on osteoclast inhibition, bisphosphonates may also have antitumor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antiangiogenic effects, but this is a controversial area. Investigations are ongoing to better define the clinically relevant effects of bisphosphonates in patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy with bisphosphonates is generally well tolerated. The most common complications are acute phase reactions, ocular inflammation, renal insufficiency, electrolyte imbalance (particularly hypocalcemia), osteonecrosis of the jaw (ONJ), rarely bone, joint or muscle pain, and POSSIBLY atrial",
"    <span class=\"nowrap\">",
"     fibrillation/stroke.",
"    </span>",
"    These complications and their management are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nephrotoxicity of bisphosphonates is both dose- and infusion time-dependent. Renal toxicity may be reduced by observing recommended infusion durations, optimizing hydration prior to bisphosphonate therapy (particularly in patients with Bence-Jones proteinuria) and avoiding concurrent nephrotoxic medications. A lower initial dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      &nbsp;is recommended for patients with preexisting renal impairment. Serum creatinine should be checked before each dose in all patients receiving IV bisphosphonates for advanced malignancy. In addition, patients receiving bisphosphonates for multiple myeloma should undergo periodic monitoring for albuminuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H6#H6\">",
"       \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Management and prevention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Osteonecrosis of the jaw (ONJ) is an uncommon but increasingly recognized complication of chronic therapy with IV high potency bisphosphonates in patients with malignancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      ONJ typically presents as pain, infection, and necrotic bone in the mandible or maxilla. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928365#H1928365\">",
"       \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Established risk factors include dental extraction, poor dental hygiene, poorly fitting dentures, and advanced periodontal disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928392#H1928392\">",
"       \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Incidence and risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Particularly because of the difficulty in treating ONJ, prevention is emphasized. All patients should be examined by a dentist and have needed dental work including removal of unsalvageable teeth, with optimization of periodontal health prior to initiating therapy, if possible. During therapy, all patients should practice good oral hygiene including daily brushing, flossing, and use of antibacterial oral rinses, and recommended dental check-ups, denture fittings, and routine cleanings. Patients should inform their dentists they are receiving bone-modifying agents so invasive dental procedures and especially extractions can be avoided while receiving active therapy. Oral exams and hygiene status should be closely monitored by the oncologist during treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H8702257#H8702257\">",
"       \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Prevention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who develop ONJ while receiving therapy with a bisphosphonate, recommendations on management (particularly the benefit of discontinuing the bisphosphonate) are hindered by a lack of evidence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928489#H1928489\">",
"       \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although effective inhibition of osteoclast activity can result in hypocalcemia and hypophosphatemia, most patients do not become hypocalcemic because of compensatory mechanisms. Patients are at higher risk of electrolyte imbalance if they have renal insufficiency, decreased compensatory mechanisms, or vitamin D deficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Calcium and vitamin D levels should be assessed and low levels corrected prior to initiating therapy with a bisphosphonate. Periodic monitoring of serum calcium, magnesium, and phosphate, as well as vitamin D levels is needed during therapy.",
"     </li>",
"     <li>",
"      If there are no contraindications, patients receiving bisphosphonates should receive calcium and vitamin D supplementation to decrease the risk of bisphosphonate-induced hypocalcemia and maintain bone health. The use of calcium and vitamin D in patients who are at risk for hypercalcemia in the setting of bone metastases is not a concern as absorption of oral calcium is regulated by parathyroid hormone, which falls as serum calcium rises.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1023245\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with breast cancer and bone metastases, bisphosphonate therapy can prevent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delay skeletal complications, and palliate bone pain. A survival benefit has not been shown. In women with metastatic breast cancer without clinically evident bone metastases, bisphosphonates do not reduce the incidence of skeletal events. Consequently, therapy with high dose bisphosphonates is recommended to begin after the identification of osseous metastases, unless as part of a clinical trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8042?source=see_link\">",
"     \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bisphosphonates can also prevent treatment-related bone loss in women receiving chemotherapy or aromatase inhibitors for breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37545?source=see_link\">",
"     \"Evaluation and management of aromatase inhibitor-induced bone loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/35/33336?source=see_link\">",
"     \"Overview of the use of osteoclast inhibitors in early breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous bisphosphonate therapy is recommended for patients with multiple myeloma and any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lytic destruction of bone or spine compression fracture from osteopenia on plain radiograph or imaging studies",
"     </li>",
"     <li>",
"      Osteopenia on bone mineral density studies but no evidence of lytic bone destruction",
"     </li>",
"     <li>",
"      Pain due to osteolytic disease",
"     </li>",
"     <li>",
"      As an adjunct to radiation therapy, analgesics, or surgical intervention to stabilize fractures or impending fractures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=see_link\">",
"     \"The use of bisphosphonates in patients with multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link\">",
"     \"Treatment of the complications of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Lung cancer and other solid cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trial data on bisphosphonates in lung cancer and other solid tumors are more limited than for multiple myeloma, breast, and prostate cancer.",
"   </p>",
"   <p>",
"    In a placebo-controlled trial of 773 patients with skeletal metastases from cancers other than breast and prostate (including non small cell and small cell lung, renal cell, thyroid, and head and neck cancers), patients who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    had a significant reduction in the number of SREs (38 versus 47 percent) and a significantly longer time to the first event (230 versus 163 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/8\">",
"     8",
"    </a>",
"    ]. These benefits persisted with prolonged treatment and follow-up (approximately 21 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional data supporting the use of bisphosphonates in lung cancer comes from an insurance claims database that compared 365 patients with bone metastases who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    to 2174 who did not receive zoledronic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/10\">",
"     10",
"    </a>",
"    ]. Those receiving the bisphosphonates had a significantly reduced incidence of skeletal complications, and a longer time to develop such complications.",
"   </p>",
"   <p>",
"    Based upon these results, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , the only bisphosphonate with clinical data, is recommended in selected patients with advanced lung cancer, renal cancer, and other solid tumors with evidence of bone metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/1,4,11\">",
"     1,4,11",
"    </a>",
"    ]. Patients should be selected for treatment based upon assessment of their expected survival time and an expectation of overall palliative benefit. This includes the risk of skeletal events, which is increased by occurrence of a previous SRE, and the rate of bone turnover as measured by bone biomarkers (urinary NTX and bone-ALP) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In addition to their benefit in reducing the rate of SREs, bisphosphonates may reduce bone pain from skeletal metastases and improve quality of life, a finding that has been best demonstrated in patients with metastatic thyroid cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'New approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal duration of bisphosphonate treatment is controversial. We continue such treatment as long as feasible to minimize the frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    postpone the development of SREs.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    as an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    in these patients is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H538651028\">",
"    <span class=\"h3\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of bisphosphonates in preventing osteoporosis in men treated with androgen deprivation therapy for prostate cancer and for men with bone metastases are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H7#H7\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Osteoporosis and bone fractures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/36999?source=see_link&amp;anchor=H19250956#H19250956\">",
"     \"Management of bone metastases in advanced prostate cancer\", section on 'Osteoclast inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DENOSUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to bisphosphonates, osteoclast inhibition can also be achieved by targeting receptor activator of nuclear factor kappa B ligand (RANKL), a key component in the pathway for osteoclast formation and activation. Expression of RANKL in bone is also thought to contribute to the development of bone metastases by binding to its receptor (receptor activator of nuclear factor kappa B, RANK) on the surface of tumor cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31737?source=see_link&amp;anchor=H3#H3\">",
"     \"Mechanisms of bone metastases\", section on 'Bone as a preferential site for metastasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    , a monoclonal antibody targeting RANKL, has demonstrated efficacy in the management of postmenopausal osteoporosis and in patients with breast and prostate cancer who are at risk for cancer therapy-induced bone loss due to endocrine therapy with aromatase inhibitors or androgen deprivation therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22040?source=see_link\">",
"     \"Denosumab for osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37545?source=see_link\">",
"     \"Evaluation and management of aromatase inhibitor-induced bone loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H11#H11\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Denosumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In phase III trials conducted in patients with bone metastases from breast and advanced prostate cancer,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    significantly prolonged the time to a first skeletal-related event (SRE) compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8042?source=see_link&amp;anchor=H608404691#H608404691\">",
"     \"Osteoclast inhibition in the management of bone metastases from breast cancer\", section on 'Denosumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/36999?source=see_link&amp;anchor=H19252106#H19252106\">",
"     \"Management of bone metastases in advanced prostate cancer\", section on 'Prevention of skeletal related events'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    has also been studied in a variety of other malignancies, with encouraging results [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. A phase III trial compared denosumab and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    in 1776 patients with multiple myeloma or bone metastases from a solid tumor other than breast or prostate cancer (40 percent non-small cell lung cancer, 10 percent multiple myeloma, 9 percent renal cell carcinoma, 6 percent small cell lung cancer, 5 percent other tumor types) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/15\">",
"     15",
"    </a>",
"    ]. Denosumab was not significantly inferior to zoledronic acid in delaying time to first-on-study skeletal-related event (SRE, 20.6 versus 16.3 months, HR 0.84, 095% CI 0.71 to 0.98, p=0.03). However, when adjusted for multiple comparisons to test for superiority, the difference was no longer statistically significant (p=0.06). A later analysis of this trial, focusing on secondary endpoints, found that denosumab reduced the risk of radiation to bone by 22 percent relative to zoledronic acid (p = 0.026), prevented worsening of pain and pain interference (for a two point increase in the Brief Pain Inventory score, p &lt;0.05 relative to zoledronic acid), significantly reduced the frequency of a shift from",
"    <span class=\"nowrap\">",
"     no/weak",
"    </span>",
"    opioid analgesic use to strong opioids at months 3 to 5, and among those with mild or no pain at baseline, significantly delayed the time to develop moderate-to-severe pain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of the complications of multiple myeloma\", section on 'Prevention of skeletal events'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall survival and disease progression rates were similar between the two groups. However, in an exploratory analysis of the 811 patients with lung cancer (including 702 with non-small cell carcinoma [NSCLC] and 109 with small cell carcinoma [SCLC]), treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    was associated with a small but statistically significant improvement in overall survival (median 8.9 versus 7.7 months, HR 0.80, 95% CI 0.67-0.95) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/17\">",
"     17",
"    </a>",
"    ]. A similar survival benefit was observed in both NSCLC and SCLC patients. In contrast, mortality appeared to be higher with denosumab compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    in patients with multiple myeloma (HR for death 2.26, 95% CI 1.13 to 4.50), but the number of patients in this group was limited [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A patient-level meta-analysis of the three phase III trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    for metastatic bone disease in breast, prostate, or other solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/15,18,19\">",
"     15,18,19",
"    </a>",
"    ] concluded that denosumab was superior to zoledronic acid in reducing the risk of a first-on-study SRE (HR 0.83, 95% CI 0.76-0.90), and in delaying the time to a first SRE or hypercalcemia of malignancy (median 26.6 versus 19.4 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/20\">",
"     20",
"    </a>",
"    ]. Overall survival and disease progression were similar with both treatments. In contrast to zoledronic acid, denosumab did not require monitoring or dose",
"    <span class=\"nowrap\">",
"     modification/withholding",
"    </span>",
"    based on renal status and was not associated with acute phase reactions. Hypocalcemia was more common with denosumab, while osteonecrosis of the jaw occurred at a similar rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these data,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    has been approved for the treatment of patients with bone metastases from solid tumors but not multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13608/abstract/21\">",
"     21",
"    </a>",
"    ]. The recommended dose and schedule for denosumab for the prevention of SREs is 120 mg administered subcutaneously every four weeks.",
"   </p>",
"   <p>",
"    Cost and reimbursement issues may influence the choice of treatment. The cost of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    is approximately $1650 monthly based upon wholesale acquisition costs, while the cost for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (4 mg monthly) is approximately $450 per dose. However, while denosumab is more expensive, it is administered subcutaneously rather than intravenously, and may be more practical for some patients, such as those who are not receiving intravenous cancer treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1023259\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects that are shared by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    and high potency IV bisphosphonates in patients receiving these agents for advanced malignancy include osteonecrosis of the jaw (ONJ) and hypocalcemia and other electrolyte disorders. The risk of ONJ is similar for denosumab and bisphosphonates, whereas the risk of hypocalcemia is a little higher with denosumab. Recommendations for assessment and management of dental health and serial monitoring of electrolytes during therapy are similar to those in patients receiving bisphosphonates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1927316#H1927316\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Risks shared by both classes of drugs'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In contrast to bisphosphonates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    is not cleared by the kidneys, and dose adjustments and monitoring of renal function are not required or recommended during treatment. However, patients with severe renal insufficiency are more prone to hypocalcemia and should be monitored more closely for this toxicity when initiating therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H454293350#H454293350\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Renal effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcium and vitamin D levels should be assessed and low levels corrected prior to initiating therapy. If there are no contraindications (eg, preexisting hypercalcemia, recurrent renal stones), all patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    should receive calcium and vitamin D&nbsp;supplementation to prevent secondary hyperparathyroidism and hypocalcemia and to ensure sufficient calcium for bone",
"    <span class=\"nowrap\">",
"     repair/healing.",
"    </span>",
"    The use of calcium and vitamin D in patients who are at risk for hypercalcemia in the setting of bone metastases is not a concern as absorption of oral calcium is regulated by parathyroid hormone, which falls as serum calcium rises. Recommendations for intake of calcium and vitamin D dosing are covered in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link&amp;anchor=H6#H6\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Optimal intake'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced cancer are at substantial risk for skeletal complications including bone metastases and bone loss, which is often treatment-related.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone metastases are associated with a risk of skeletal-related events (SREs), which include fracture, skeletal",
"      <span class=\"nowrap\">",
"       instability/loss",
"      </span>",
"      of skeletal integrity requiring surgery or radiation, spinal cord compression, and hypercalcemia of malignancy. SREs are often used as endpoints in clinical trials investigating therapies for bone metastases. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Bone metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bisphosphonates and other osteoclast inhibitors such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      reduce the morbidity of metastatic bone disease, mainly by decreasing SREs. There may also be palliative benefit for patients with bone pain; the data are most compelling with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      and denosumab.",
"     </li>",
"     <li>",
"      The indications for bisphosphonates and other osteoclast inhibitors in patients with breast and prostate cancer and multiple myeloma are addressed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8042?source=see_link\">",
"       \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=see_link\">",
"       \"The use of bisphosphonates in patients with multiple myeloma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/8/36999?source=see_link\">",
"       \"Management of bone metastases in advanced prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend the use of an osteoclast inhibiting agent to reduce the risk of skeletal complications in patients with bone metastases from a wide variety of solid tumors, including breast and prostate cancer (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      For most patients who do not have multiple myeloma, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      as the preferred agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This recommendation is based upon data from three large randomized trials showing that denosumab improved the time to the first and subsequent SREs when compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      , although statistical superiority was shown in only two of the three trials. When cost",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reimbursement are important considerations, zoledronic acid is an acceptable alternative. For patients who have myeloma, zoledronic acid is the preferred agent. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Denosumab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Lung cancer and other solid cancers'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The recommended dose and schedule for denosumab for the prevention of SREs is 120 mg administered subcutaneously every four weeks. The dose and schedule for zoledronic acid is 4 mg IV monthly.",
"     </li>",
"     <li>",
"      Unless there are contraindications, all patients receiving bisphosphonates or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      should also receive calcium and vitamin D supplementation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Complications'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/1\">",
"      Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw 2009; 7 Suppl 3:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/2\">",
"      Domchek SM, Younger J, Finkelstein DM, Seiden MV. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 2000; 89:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/3\">",
"      Coleman RE. Uses and abuses of bisphosphonates. Ann Oncol 2000; 11 Suppl 3:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/4\">",
"      Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/5\">",
"      Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/6\">",
"      Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008; 34:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/7\">",
"      Gnant M, Dubsky P, Fitzal F, et al. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit? Clin Breast Cancer 2009; 9 Suppl 1:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/8\">",
"      Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21:3150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/9\">",
"      Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004; 100:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/10\">",
"      Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008; 113:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/11\">",
"      De Marinis F, Eberhardt W, Harper PG, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 2009; 4:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/12\">",
"      Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/13\">",
"      Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23:4925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/14\">",
"      Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/15\">",
"      Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/16\">",
"      Vadhan-Raj S, von Moos R, Fallowfield LJ, et al. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol 2012; 23:3045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/17\">",
"      Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012; 7:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/18\">",
"      Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/19\">",
"      Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13608/abstract/20\">",
"      Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48:3082.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s007lbl.pdf (Accessed on November 22, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2801 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-9D0B6BF364-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13608=[""].join("\n");
var outline_f13_18_13608=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BONE DISEASE IN PATIENTS WITH METASTATIC CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bone metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bone loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BISPHOSPHONATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1023245\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Lung cancer and other solid cancers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H538651028\">",
"      - Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DENOSUMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1023259\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2801\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2801|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/30/15852\" title=\"figure 1\">",
"      Bisphosphonate chem struc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2801|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/17/21787\" title=\"table 1\">",
"      Typical radiographic response in bone to select tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22040?source=related_link\">",
"      Denosumab for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37545?source=related_link\">",
"      Evaluation and management of aromatase inhibitor-induced bone loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/36999?source=related_link\">",
"      Management of bone metastases in advanced prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31737?source=related_link\">",
"      Mechanisms of bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8042?source=related_link\">",
"      Osteoclast inhibition in the management of bone metastases from breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/35/33336?source=related_link\">",
"      Overview of the use of osteoclast inhibitors in early breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=related_link\">",
"      The use of bisphosphonates in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=related_link\">",
"      Treatment of the complications of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_18_13609="Clinical manifestations of peptic ulcer disease";
var content_f13_18_13609=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of peptic ulcer disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/18/13609/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/18/13609/contributors\">",
"     Andrew H Soll, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/18/13609/contributors\">",
"     Nimish B Vakil, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/18/13609/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/18/13609/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/18/13609/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/18/13609/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/18/13609/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptic ulcers may present with dyspeptic or other gastrointestinal symptoms or may be completely asymptomatic, sometimes until complications such as hemorrhage or perforation occur. The symptoms associated with peptic ulcers are not sensitive or specific and the differential diagnosis is broad. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the clinical manifestations of peptic ulcer disease and the differential diagnosis that should be considered. The methods used to establish the diagnosis, the association with H. pylori infection, and an approach to therapy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19113?source=see_link\">",
"     \"Epidemiology and etiology of peptic ulcer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24919?source=see_link\">",
"     \"Diagnosis of peptic ulcer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of peptic ulcer disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19113?source=see_link\">",
"     \"Epidemiology and etiology of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pragmatic definition of \"dyspepsia\" is the presence of symptoms that the clinician suspects are coming from the upper gastrointestinal (GI) tract [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/1\">",
"     1",
"    </a>",
"    ]. Peptic ulcers can present with any of the three dyspeptic symptom patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ulcer-like or acid dyspepsia (burning pain; epigastric hunger-like pain; relief with food, antacids,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antisecretory agents)",
"     </li>",
"     <li>",
"      Food-provoked dyspepsia or indigestion (postprandial epigastric discomfort and fullness, belching, early satiety, nausea, and occasional vomiting)",
"     </li>",
"     <li>",
"      Reflux-like dyspepsia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These symptom patterns probably reflect similar mechanisms of altered visceral sensation and possibly dysmotility. A study using a self-report questionnaire examined these three dyspeptic symptom patterns in a general population sample [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/2\">",
"     2",
"    </a>",
"    ]. Ulcer-like dyspepsia was most common, but 43 percent of the subjects with dyspepsia could be classified into more than one subgroup. These patterns overlap considerably and have poor predictive value for specific diagnoses found at endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. However, defining the patterns can help the clinician determine if symptoms are coming from the upper GI tract, and, therefore, guide evaluation and treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association of symptomatic peptic ulcers with increased visceral sensation and possibly dysmotility suggests a parallel with functional dyspepsia, which could account for some of the observed symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/6\">",
"     6",
"    </a>",
"    ]. However, patients with peptic ulcers respond much better to treatment than do patients with functional dyspepsia, indicating that the ulcer subset is likely distinct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H930489\">",
"    <span class=\"h2\">",
"     Ulcer-like dyspepsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper abdominal pain or discomfort is the most prominent symptom in patients with peptic ulcers; approximately 80 percent of patients with endoscopically diagnosed ulcers have epigastric pain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/7\">",
"     7",
"    </a>",
"    ]. Although discomfort from ulcers is usually centered in the epigastrium, it may occasionally localize to the right or left upper quadrants or the hypochondrium [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/8\">",
"     8",
"    </a>",
"    ]. Radiation of pain to the back may occur, but back pain as the primary symptom is atypical. Although ulcer pain is often burning, gnawing, or hunger-like in quality, the discomfort can be vague or crampy. In the era when ulcer patients were essentially untreated, symptoms were observed to occur in clusters lasting a few weeks followed by symptom-free periods of weeks or months.",
"   </p>",
"   <p>",
"    The \"classic\" pain of duodenal ulcers (DU) occurs when acid is secreted in the absence of a food buffer. Food is usually well emptied by two to three hours after meals, but food-stimulated acid secretion persists for three to five hours; thus, classic DU symptoms occur two to five hours after meals. Symptoms also classically occur at night, between about 11 PM and 2 AM, when the circadian stimulation of acid secretion is maximal. The ability of alkali, food, and antisecretory agents to produce relief suggests a role for acid in symptom generation. Thus, \"acid dyspepsia\" is a fitting term. There is no firm evidence supporting the venerable teaching that gastric ulcer is associated with more severe pain occurring soon after meals, with less frequent relief by antacids or food. Such differences are probably related to the level of visceral sensitization, as considered below.",
"   </p>",
"   <p>",
"    At least a portion of patients with DUs develop symptoms when acid bathes their duodenal mucosa. This was demonstrated in a randomized, double-blind trial of 40 patients with DUs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/9\">",
"     9",
"    </a>",
"    ]. The trial found that 16 patients (40 percent) developed typical acid pain upon bathing the ulcer through the endoscope with 0.1 N hydrochloric acid, while only four patients (10 percent) complained of pain with saline. By comparison, hydrochloric acid infusion into the duodenum did not produce pain in patients without DUs. However, the pain experienced by patients with peptic ulcers is mediated by factors in addition to acid bathing an ulcer crater. Although the secretory rates and concentrations of acid in patients with DUs are higher than those in controls, the overlap is considerable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. One can speculate that the symptoms of acid dyspepsia reflect, at least in part, sensitization of visceral afferents to luminal acid exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H930571\">",
"    <span class=\"h2\">",
"     Food-provoked dyspepsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptic ulcers can also be associated with food-provoked symptoms, such as epigastric pain that worsens with eating, postprandial belching and epigastric fullness, early satiety, fatty food intolerance, nausea, and occasional vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Food-provoked symptoms in ulcer patients appear to reflect a combination of visceral sensitization and gastroduodenal dysmotility. One study found that symptomatic peptic ulcers were associated with increased visceral sensation of the upper GI tract, evident by an augmented symptomatic response to ingestion of a liquid nutrient meal in patients with symptomatic peptic ulcers, compared with patients with asymptomatic ulcers and healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Gastroesophageal reflux and other GI symptoms",
"    </strong>",
"    &mdash; Peptic ulcers are frequently associated with gastroesophageal reflux; a systematic review found that 46 percent of patients with endoscopically diagnosed ulcers had heartburn or acid regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4214164\">",
"    <span class=\"h2\">",
"     Other GI symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/7\">",
"     7",
"    </a>",
"    ] and symptoms typical of irritable bowel syndrome (eg, crampy, periumbilical abdominal pain related to altered bowel function and often relieved by decompressing the colon) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/14\">",
"     14",
"    </a>",
"    ] are also common in patients with peptic ulcers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=see_link\">",
"     \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Silent ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frequently, peptic ulcers are asymptomatic. Between 43 and 87 percent of patients with bleeding peptic ulcers present without antecedent dyspepsia or other heralding GI symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/6,15,16\">",
"     6,15,16",
"    </a>",
"    ]. Ulcer perforation also frequently occurs without antecedent symptoms. This \"silent\" presentation may be more frequent in elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/7,15\">",
"     7,15",
"    </a>",
"    ] and possibly in individuals consuming nonsteroidal antiinflammatory drugs (NSAIDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/17\">",
"     17",
"    </a>",
"    ]. Consistent with these findings, patients with a history of bleeding peptic ulcers had low levels of background GI symptoms and symptomatic responses to a nutrient meal that were comparable to healthy controls and much less than symptomatic ulcer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endoscopic surveys of asymptomatic individuals also detect frequent silent ulcers. For example, in a study from Taiwan, 11 percent of 6457 subjects undergoing screening endoscopy had a peptic ulcer, and 70 percent of those subjects were asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931262\">",
"    <span class=\"h2\">",
"     Predictive value of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with peptic ulcers, there is often a poor correlation of the presence of endoscopic ulceration with symptoms. Longitudinal studies have shown that as many as 40 percent of patients with endoscopically healed ulcers have persistent symptoms, while 15 to 44 percent of those who become symptom-free still have an ulcer crater at endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Thus, the disappearance of symptoms does not guarantee ulcer healing, nor does the persistence of symptoms consistently predict the presence of an ulcer crater.",
"   </p>",
"   <p>",
"    In patients with uninvestigated dyspepsia, symptoms do not accurately predict the presence or absence of organic disease. In one study, a clinical diagnosis of peptic ulcer disease had a positive likelihood ratio for the presence of endoscopic peptic ulceration of 2.2 to 2.9, whereas a clinical diagnosis of no peptic ulcer disease had a negative likelihood ratio of 0.45 to 0.48 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link&amp;anchor=H21#H21\">",
"     \"Glossary of common biostatistical and epidemiological terms\", section on 'Likelihood ratio'",
"    </a>",
"    .) Clinical diagnoses have very poor predictive value for two reasons: symptoms are nonspecific and overlapping and the pre-test prevalence of peptic ulcer disease among patients with undiagnosed dyspepsia in developed countries has dropped to as low as 4 to 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Despite this low accuracy of the clinical diagnosis of organic disease, we emphasize a point made above: a detailed clinical history helps clinicians to discriminate between symptoms coming from the upper or lower GI tract versus symptoms of cardiac, pulmonary, or fibromuscular origin, thereby guiding diagnosis and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ulcer complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of complications, especially in the absence of NSAID use, are associated with chronic peptic ulcers, which are surrounded by fibrosis and have presumably been present for months or longer. NSAID ulcers sometimes lack surrounding fibrosis and are likely acute, developing and presenting with complications over the first days or weeks of NSAID use. Similarly, stress ulcers developing in the ICU setting can be acute, without surrounding fibrosis.",
"   </p>",
"   <p>",
"    Complications may be heralded by new ulcer symptoms or a change in symptoms or may occur in the absence of typical symptoms (silent ulcers). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40282?source=see_link\">",
"     \"Overview of the complications of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms that suggest complications related to a peptic ulcer include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Penetrating ulcers classically present with a shift from the typical vague visceral discomfort to a more localized and intense pain that radiates to the back and is not relieved by food or antacids.",
"     </li>",
"     <li>",
"      The sudden development of severe, diffuse abdominal pain may indicate perforation.",
"     </li>",
"     <li>",
"      Vomiting is the cardinal feature present in most cases of pyloric outlet obstruction.",
"     </li>",
"     <li>",
"      Hemorrhage may be heralded by nausea, hematemesis, melena, or dizziness.",
"     </li>",
"     <li>",
"      Gastrocolic fistula, a very rare complication, can present with halitosis, feculent vomiting, postprandial diarrhea, dyspepsia, and sometimes weight loss [",
"      <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many patients underestimate the significance of their symptoms and fail to present in a timely fashion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     NSAID-induced ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although NSAIDs can cause dyspepsia and peptic ulcers, there is frequently dissociation between symptoms and pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/26\">",
"     26",
"    </a>",
"    ]. As an example, one study evaluated the appearance of the gastroduodenal mucosa in 65 patients treated with a variety of NSAIDs for at least six consecutive weeks to treat osteoarthritis or rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/27\">",
"     27",
"    </a>",
"    ]. Dyspeptic symptoms were more common in patients with a completely normal endoscopy compared with those with an abnormal endoscopy (19 versus 9 percent). In addition, only 3 of the 10 patients with ulcers had dyspeptic symptoms.",
"   </p>",
"   <p>",
"    By contrast, dyspepsia appearing during a controlled trial of NSAID treatment in high-risk patients has been observed to predict ulcer recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/28\">",
"     28",
"    </a>",
"    ]. Thus, although one can expect frequent dissociation between symptoms and ulcers, the development of gastrointestinal symptoms in a patient taking NSAIDs is an important clue to an underlying ulcer and should prompt evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Atypical ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of atypical presentations of peptic ulcer may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Giant ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most peptic ulcers are less than 1 to 2 cm in diameter; ulcers more than 2 cm in diameter are termed giant ulcers. Giant duodenal ulcers are usually located on the posterior wall. They may present with a prolonged typical history, pain radiating to the back, or few, if any, symptoms. Reversible anorexia and weight loss can be observed in the absence of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Giant ulcers are frequently complicated by bleeding, posterior penetration, and, depending upon location, by pyloric obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. One study comparing 62 patients with giant gastric ulcers (defined as &ge;3 cm) with 476 patients with smaller gastric ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/30\">",
"     30",
"    </a>",
"    ], found that the giant ulcers were more prone to severe hemorrhage (44 versus 27 percent) and penetration into contiguous organs (45 versus 10 percent). In addition, the risk of microscopic malignancy in the macroscopically benign-appearing giant ulcer was significantly higher (13 versus 3 percent). Other studies have also confirmed that malignancy is more frequent in giant compared with smaller ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of a visible vessel in the ulcer crater also predicts the clinical course of giant duodenal ulcers. In one study, 7 of 15 patients with a visible vessel required eventual operation, compared with only 1 of 13 patients without a visible vessel [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are conflicting data regarding demographics and risk factors associated with giant ulcers, which probably reflect the time frame and population under investigation. In one study, giant ulcers occurred more frequently in older subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/29\">",
"     29",
"    </a>",
"    ] and in association with NSAID consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/31\">",
"     31",
"    </a>",
"    ]. However, in another study, methamphetamine or cocaine use, as well as NSAIDs, were major risk factors (the odds ratio for stimulant use was 9.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/33\">",
"     33",
"    </a>",
"    ]. This latter study also found that giant ulcers were inversely related to patient age, possibly indicating that the demographics of drug users may have influenced the outcomes.",
"   </p>",
"   <p>",
"    Comorbidities appear to be an important contributing factor in the development of giant ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/29\">",
"     29",
"    </a>",
"    ]. Giant duodenal or prepyloric ulcers have been reported in association with end-stage renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/34\">",
"     34",
"    </a>",
"    ], orthotopic lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/35\">",
"     35",
"    </a>",
"    ], and Crohn's disease. The ulcer symptoms may be the presenting complaint in patients with Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/36\">",
"     36",
"    </a>",
"    ]. Mechanisms were not defined, but probably include poor nutrition, decreased mucosal blood flow, and poor healing.",
"   </p>",
"   <p>",
"    H. pylori infection is certainly an important factor in some giant ulcers, but no prospective, controlled studies have examined its prevalence. Of the 23 patients who underwent antral biopsy in one study, only nine were positive for H. pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/32\">",
"     32",
"    </a>",
"    ], suggesting the importance of other factors, such as NSAID use and comorbid conditions that predispose to ulceration.",
"   </p>",
"   <p>",
"    Giant ulcers also heal more slowly and relapse more frequently than smaller ulcers, especially in patients with comorbid conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/29\">",
"     29",
"    </a>",
"    ]. Medical management should include four elements: detection and treatment of H. pylori, if present; aggressive efforts to detect and discontinue NSAID use since healing is very difficult with continued use; exclusion of malignancy, especially for gastric ulcers; and treatment with proton pump inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\", section on 'Giant ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pyloric channel ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcers located in the pyloric channel may be associated with pain occurring shortly after eating, poor relief by antacids, and vomiting. Vomiting may occur as a result of pyloric obstruction or dysfunction. Juxtapyloric ulcers, which occur at or within 2 cm of the pylorus, often present with complications. In one series, for example, patients with pyloric channel ulcers were more likely to undergo surgery than those with ulcers in the duodenal bulb [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Postbulbar ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duodenal ulcers are generally located in the duodenal bulb within 2 to 3 cm of the pylorus. Ulcers distal to the duodenal bulb (postbulbar ulcers) were found in 10 percent of cases in an autopsy series, but in only 15 of 4016 radiographic examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/38\">",
"     38",
"    </a>",
"    ]. Ulcers beyond the second portion of the duodenum and into the proximal jejunum are characteristic of a gastrinoma and possibly other hypersecretory states. In one report of patients with gastrinomas, 75 percent of ulcers were in the first portion of the duodenum, 14 percent in the distal duodenum, and 11 percent in the jejunum [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No clinical features clearly distinguish postbulbar ulcers, although a higher rate of complications has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/38\">",
"     38",
"    </a>",
"    ]. The differential diagnosis includes diverticula, adhesive bands, annular pancreas, and neoplasia of the pancreas and duodenum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Multiple ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple simultaneous ulcers occur in 2 to 20 percent of patients with peptic ulcers (",
"    <a class=\"graphic graphic_picture graphicRef68358 \" href=\"UTD.htm?13/16/13583\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In one series, multiple duodenal ulcers were associated with a higher male to female ratio, more patients with a late-onset (ulcer symptoms starting after age 30 years), chronic cigarette smoking, and moderate to severe deformity of the duodenal bulb [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/42\">",
"     42",
"    </a>",
"    ]. Multiple ulcers are often clustered together, suggesting that local pathogenic mechanisms that involve compromised mucosal resistance to injury or impaired healing are important for the development of this entity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/41\">",
"     41",
"    </a>",
"    ]. NSAID use and gastrinoma should also be considered when multiple ulcers are encountered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptic ulcers must be differentiated from other disorders that cause symptoms in the upper abdomen and from ulcerative lesions of the stomach and duodenum that are secondary to diseases involving the gastroduodenal mucosal itself (",
"    <a class=\"graphic graphic_table graphicRef65698 \" href=\"UTD.htm?3/22/3436\">",
"     table 1",
"    </a>",
"    ). The specific causes of ulcerative lesions of the stomach and duodenum must be identified whenever possible, since effective therapy is available for many cases secondary to other specific causes. Some of these conditions can be diagnosed by gross and histologic assessment of the gastric mucosa and are described below. In addition, a variety of other conditions are associated with peptic ulcers, which may or may not be detectable by biopsy or visual inspection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=see_link\">",
"     \"Unusual causes of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Functional dyspepsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common type of dyspepsia encountered in primary care and gastroenterology practice is functional (idiopathic) dyspepsia, also referred to as nonulcer dyspepsia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Although developed by an international committee for research purposes, the following definition of functional dyspepsia (Rome III criteria) has clinical utility [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of symptoms thought to originate in the gastroduodenal region, in the absence of any organic, systemic, or metabolic disease that is likely to explain the symptoms (eg, acid-peptic or neoplastic disease of the stomach, esophagus or duodenum, or disease of the pancreas or hepatobiliary system)",
"     </li>",
"     <li>",
"      Symptoms include epigastric discomfort or pain, postprandial fullness, and early satiation",
"     </li>",
"     <li>",
"      Patients with a past history of documented chronic peptic ulcer disease should not be classified as having functional dyspepsia at least until the relationship between these entities is clarified",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no diagnostic tests for functional dyspepsia, and, as noted above, it is not possible to clinically distinguish ulcer from nonulcer dyspepsia. As a result, the diagnosis is made upon the exclusion of other causes of dyspepsia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Gastric carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to differentiate between gastric carcinoma and peptic ulcer at an early stage, when the cancer is operable and potentially curable. Gastric malignancy infrequently causes chronic dyspepsia. However, the possibility should be considered, particularly in patients over 45 to 55 years of age and in those who have the following \"alarm symptoms\" or risk factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unintended weight loss",
"     </li>",
"     <li>",
"      Bleeding",
"     </li>",
"     <li>",
"      Anemia",
"     </li>",
"     <li>",
"      Dysphagia",
"     </li>",
"     <li>",
"      Odynophagia",
"     </li>",
"     <li>",
"      Hematemesis",
"     </li>",
"     <li>",
"      A palpable abdominal mass or lymphadenopathy",
"     </li>",
"     <li>",
"      Persistent vomiting",
"     </li>",
"     <li>",
"      Unexplained iron deficiency anemia",
"     </li>",
"     <li>",
"      Family history of upper gastrointestinal cancer",
"     </li>",
"     <li>",
"      Previous gastric surgery",
"     </li>",
"     <li>",
"      Jaundice",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although early gastric cancer is usually asymptomatic, it can present with dyspepsia that is indistinguishable from symptoms due to peptic ulcers. New onset of symptoms or a recent change in pattern should raise concern for possible neoplasia. In general, compared with advanced disease, early gastric cancer has fewer associated symptoms and a much better prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link\">",
"     \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A review of published studies noted the following incidence of symptoms in European patients with early gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Epigastric pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dyspepsia, similar to peptic ulcer disease &ndash; 65 to 90 percent",
"     </li>",
"     <li>",
"      Nausea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting &ndash; 6 to 40 percent",
"     </li>",
"     <li>",
"      Anorexia &ndash; 12 to 40 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The alarm signs or symptoms suggestive of invasive disease, such as anemia or weight loss, occurred less frequently (5 to 15 percent and 4 to 40 percent, respectively).",
"   </p>",
"   <p>",
"    Unfortunately, alarm symptoms are not accurate predictors of underlying pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/47\">",
"     47",
"    </a>",
"    ]. However, they probably increase the chance of finding organic disease and should be sought and appropriately evaluated. Cancers missed on endoscopy have been associated with alarm symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other neoplastic lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other neoplastic processes can mimic peptic ulcers, presenting with dyspepsia or ulcers, such as gastric lymphoma; leiomyosarcoma; primary gastric and metastatic malignant melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]; and metastatic renal cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Drug-induced dyspepsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous drugs can cause dyspepsia, epigastric distress, nausea, or vomiting. These include NSAIDs, with or without ulceration,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , and digitalis. Caffeine, coffee, alcohol, and smoking can also contribute to symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Infiltrative or granulomatous diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infiltrative or granulomatous diseases can present with dyspepsia and occasionally ulceration. Involvement of the stomach is the most common site of sarcoidosis in the gastrointestinal tract, almost always occurring in association with pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Ulceration resembling peptic ulcer disease can occur with or without enlargement of mucosal folds. Eosinophilic granuloma and granulomatosis with polyangiitis (Wegener's granulomatosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/55\">",
"     55",
"    </a>",
"    ] can also present in this fashion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17638?source=see_link\">",
"     \"Gastrointestinal sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertrophic gastritis (including M&eacute;n&eacute;trier's disease) may present with dyspeptic symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2984?source=see_link\">",
"     \"Large gastric folds: Hyperplastic and nonhyperplastic gastropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Crohn's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crohn's disease may involve the stomach or duodenum and produce symptoms and a radiographic appearance that mimics peptic ulcers (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78617 \" href=\"UTD.htm?25/13/25823\">",
"     image 1",
"    </a>",
"    ). Isolated gastroduodenal Crohn's is uncommon; radiographic abnormalities are usually present in more distal portions of the duodenum and the small intestine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric and duodenal tuberculosis involving the mucosa can present with ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. The diagnosis is generally difficult to make since superficial biopsies do not detect caseating granulomata, which are often submucosal, and the acid-fast stain may be negative. Thus, a high level of suspicion is necessary.",
"   </p>",
"   <p>",
"    Other infections have also been associated with chronic ulcers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mycobacterium avium intracellulare [",
"      <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/59\">",
"       59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=see_link\">",
"       \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Strongyloidiasis can produce upper abdominal pain and nausea; in addition, gastric ulcers with bleeding have been reported with infiltration in the ulcerated mucosa [",
"      <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link\">",
"       \"Strongyloidiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Giardiasis may produce upper abdominal discomfort, nausea, and anorexia; these symptoms are often associated with diarrhea and occasionally evidence of malabsorption (",
"      <a class=\"graphic graphic_picture graphicRef72213 \" href=\"UTD.htm?17/32/17927\">",
"       picture 2",
"      </a>",
"      ). Dyspeptic symptoms may persist over months, interspersed with periods of diarrhea lasting a few days. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Duodenal neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duodenal carcinoma is very uncommon, but can occasionally present with gastrointestinal bleeding or as an apparently benign ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. However, most cases present as a mass lesion rather an ulcer. Localized duodenal lymphoma can also mimic a duodenal ulcer and respond to ulcer therapy for a period of time [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13609/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Associated diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of disorders have been associated with peptic ulcer disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=see_link\">",
"     \"Unusual causes of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=see_link\">",
"       \"Patient information: Peptic ulcers (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=see_link\">",
"       \"Patient information: H. pylori infection (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/46/1763?source=see_link\">",
"       \"Patient information: Gastritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"       \"Patient information: Peptic ulcer disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"       \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic peptic ulcers most commonly present with epigastric pain or indigestion. These symptoms are not specific and the differential diagnosis is broad. However, peptic ulcers are commonly asymptomatic. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Silent ulcers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The \"classic\" epigastric pain of duodenal ulcers occurs when acid is secreted in the absence of a food buffer. Classic symptoms occur two to five hours after meals or on an empty stomach. Symptoms also occur at night, between 11 PM and 2 AM, when the circadian stimulation of acid secretion is maximal. (See",
"      <a class=\"local\" href=\"#H930489\">",
"       'Ulcer-like dyspepsia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peptic ulcers may also be associated with symptoms of indigestion (ie, food-provoked epigastric discomfort and fullness, early satiety, and nausea). The mechanism is probably visceral sensitization. (See",
"      <a class=\"local\" href=\"#H930571\">",
"       'Food-provoked dyspepsia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications may be heralded by new ulcer symptoms or a change in symptoms or may occur in the absence of typical symptoms. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Ulcer complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms of peptic ulcers are neither sensitive nor specific, and, with the very low prevalence of peptic ulcer in patients with uninvestigated dyspepsia, the clinical evaluation has little predictive value for the presence of a peptic ulcer. However, the clinical assessment is essential to discriminate symptoms coming from the upper GI tract versus symptoms of cardiac, pulmonary, or fibromuscular origin. (See",
"      <a class=\"local\" href=\"#H931262\">",
"       'Predictive value of symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/1\">",
"      Rabeneck L. Managing dyspepsia: is prompt endoscopy the way to go? Gastroenterology 1995; 108:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/2\">",
"      Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ 3rd. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/3\">",
"      Westbrook JI, McIntosh JH, Duggan JM. Accuracy of provisional diagnoses of dyspepsia in patients undergoing first endoscopy. Gastrointest Endosc 2001; 53:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/4\">",
"      Heikkinen M, Pikkarainen P, Eskelinen M, Julkunen R. GPs' ability to diagnose dyspepsia based only on physical examination and patient history. Scand J Prim Health Care 2000; 18:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/5\">",
"      Moayyedi P, Talley NJ, Fennerty MB, Vakil N. Can the clinical history distinguish between organic and functional dyspepsia? JAMA 2006; 295:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/6\">",
"      Gururatsakul M, Holloway RH, Talley NJ, Holtmann GJ. Association between clinical manifestations of complicated and uncomplicated peptic ulcer and visceral sensory dysfunction. J Gastroenterol Hepatol 2010; 25:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/7\">",
"      Barkun A, Leontiadis G. Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. Am J Med 2010; 123:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/8\">",
"      Earlam R. A computerized questionnaire analysis of duodenal ulcer symptoms. Gastroenterology 1976; 71:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/9\">",
"      Kang JY, Yap I, Guan R, Tay HH. Acid perfusion of duodenal ulcer craters and ulcer pain: a controlled double blind study. Gut 1986; 27:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/10\">",
"      Peterson WL, Barnett CC, Evans DJ Jr, et al. Acid secretion and serum gastrin in normal subjects and patients with duodenal ulcer: the role of Helicobacter pylori. Am J Gastroenterol 1993; 88:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/11\">",
"      Corinaldesi R, Stanghellini V, Paparo GF, et al. Gastric acid secretion and gastric emptying of liquids in 99 male duodenal ulcer patients. Dig Dis Sci 1989; 34:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/12\">",
"      Savarino V, Mela GS, Scalabrini P, et al. 24-hour study of intragastric acidity in duodenal ulcer patients and normal subjects using continuous intraluminal pH-metry. Dig Dis Sci 1988; 33:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/13\">",
"      Merki HS, Fimmel CJ, Walt RP, et al. Pattern of 24 hour intragastric acidity in active duodenal ulcer disease and in healthy controls. Gut 1988; 29:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/14\">",
"      Sj&ouml;din I, Svedlund J, Dotevall G, Gillberg R. Symptom profiles in chronic peptic ulcer disease. A detailed study of abdominal and mental symptoms. Scand J Gastroenterol 1985; 20:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/15\">",
"      Matthewson K, Pugh S, Northfield TC. Which peptic ulcer patients bleed? Gut 1988; 29:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/16\">",
"      Wilcox CM, Clark WS. Features associated with painless peptic ulcer bleeding. Am J Gastroenterol 1997; 92:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/17\">",
"      Hilton D, Iman N, Burke GJ, et al. Absence of abdominal pain in older persons with endoscopic ulcers: a prospective study. Am J Gastroenterol 2001; 96:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/18\">",
"      Lu CL, Chang SS, Wang SS, et al. Silent peptic ulcer disease: frequency, factors leading to \"silence,\" and implications regarding the pathogenesis of visceral symptoms. Gastrointest Endosc 2004; 60:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/19\">",
"      Ippoliti AF, Sturdevant RA, Isenberg JI, et al. Cimetidine versus intensive antacid therapy for duodenal ulcer: a multicenter trial. Gastroenterology 1978; 74:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/20\">",
"      Jorde R, Bostad L, Burhol PG. Asymptomatic gastric ulcer: a follow-up study in patients with previous gastric ulcer disease. Lancet 1986; 1:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/21\">",
"      Vakil N, Talley N, van Zanten SV, et al. Cost of detecting malignant lesions by endoscopy in 2741 primary care dyspeptic patients without alarm symptoms. Clin Gastroenterol Hepatol 2009; 7:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/22\">",
"      Aro P, Storskrubb T, Ronkainen J, et al. Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol 2006; 163:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/23\">",
"      Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003; 17:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/24\">",
"      Zagari RM, Law GR, Fuccio L, et al. Dyspeptic symptoms and endoscopic findings in the community: the Loiano-Monghidoro study. Am J Gastroenterol 2010; 105:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/25\">",
"      Laosebikan AO, Govindasamy V, Chinnery G, et al. Giant gastric ulcer: an endoscopic roller coaster. Gut 2005; 54:468, 509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/26\">",
"      Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991; 114:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/27\">",
"      Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/28\">",
"      Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004; 127:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/29\">",
"      Raju GS, Bardhan KD, Royston C, Beresford J. Giant gastric ulcer: its natural history and outcome in the H2RA era. Am J Gastroenterol 1999; 94:3478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/30\">",
"      Chua CL, Jeyaraj PR, Low CH. Relative risks of complications in giant and nongiant gastric ulcers. Am J Surg 1992; 164:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/31\">",
"      Collen MJ, Santoro MJ, Chen YK. Giant duodenal ulcer. Evaluation of basal acid output, nonsteroidal antiinflammatory drug use, and ulcer complications. Dig Dis Sci 1994; 39:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/32\">",
"      Fischer DR, Nussbaum MS, Pritts TA, et al. Use of omeprazole in the management of giant duodenal ulcer: results of a prospective study. Surgery 1999; 126:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/33\">",
"      Pecha RE, Prindiville T, Pecha BS, et al. Association of cocaine and methamphetamine use with giant gastroduodenal ulcers. Am J Gastroenterol 1996; 91:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/34\">",
"      Borra S, Gavani S, Kleinfeld M. Giant peptic ulcers in patients with chronic renal failure. Mt Sinai J Med 1990; 57:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/35\">",
"      Lipson DA, Berlin JA, Palevsky HI, et al. Giant gastric ulcers and risk factors for gastroduodenal mucosal disease in orthotopic lung transplant patients. Dig Dis Sci 1998; 43:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/36\">",
"      Moonka D, Lichtenstein GR, Levine MS, et al. Giant gastric ulcers: an unusual manifestation of Crohn's disease. Am J Gastroenterol 1993; 88:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/37\">",
"      Elashoff JD, Van Deventer G, Reedy TJ, et al. Long-term follow-up of duodenal ulcer patients. J Clin Gastroenterol 1983; 5:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/38\">",
"      COOKE L, HUTTON CF. Postbulbar duodenal ulceration. Lancet 1958; 1:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/39\">",
"      Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med 1995; 46:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/40\">",
"      Boyle JD. The Veterans Administration Cooperative Study on Gastric Ulcer. 8. Multiple gastric ulcers. Gastroenterology 1971; 61:Suppl 2:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/41\">",
"      Cappell MS. Profound spatial clustering of simultaneous peptic ulcers. Gut 1989; 30:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/42\">",
"      Hui WM, Lam SK. Multiple duodenal ulcer: natural history and pathophysiology. Gut 1987; 28:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/43\">",
"      Talley NJ, Colin-Jones D, Koch KL, et al. Functional dyspepsia: A classification with guidelines for diagnosis and management. Gastroenterol Int 1992; 4:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/44\">",
"      Scolapio JS, Camilleri M. Nonulcer dyspepsia. Gastroenterologist 1996; 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/45\">",
"      Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/46\">",
"      Everett SM, Axon AT. Early gastric cancer in Europe. Gut 1997; 41:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/47\">",
"      Vakil N, Moayyedi P, Fennerty MB, Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology 2006; 131:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/48\">",
"      Raftopoulos SC, Segarajasingam DS, Burke V, et al. A cohort study of missed and new cancers after esophagogastroduodenoscopy. Am J Gastroenterol 2010; 105:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/49\">",
"      Germano D, Rosati G, Romano R, et al. Primary gastric melanoma presenting as a double ulcer. J Clin Gastroenterol 2004; 38:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/50\">",
"      Noraidah M, Jasmi AY. Malignant melanoma of the gastrointestinal tract presenting as a bleeding gastric ulcer. Malays J Pathol 2003; 25:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/51\">",
"      Mascarenhas B, Konety B, Rubin JT. Recurrent metastatic renal cell carcinoma presenting as a bleeding gastric ulcer after a complete response to high-dose interleukin-2 treatment. Urology 2001; 57:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/52\">",
"      Aga R, McCarthy JH. Persistent granulomatous gastritis. Br J Clin Pract 1990; 44:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/53\">",
"      Fireman Z, Sternberg A, Yarchovsky Y, et al. Multiple antral ulcers in gastric sarcoid. J Clin Gastroenterol 1997; 24:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/54\">",
"      Farman J, Ramirez G, Rybak B, et al. Gastric sarcoidosis. Abdom Imaging 1997; 22:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/55\">",
"      Arista S, Sailler L, Astudillo L. Relapsing esophageal and gastric ulcers revealing Wegener's granulomatosis. Am J Med 2005; 118:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/56\">",
"      Regan F, Tran T. Duodenal tuberculosis--a continuing diagnostic challenge. Postgrad Med J 1990; 66:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/57\">",
"      Weissman D, Gumaste VV, Dave PB, Keh W. Bleeding from a tuberculous gastric ulcer. Am J Gastroenterol 1990; 85:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/58\">",
"      Tromba JL, Inglese R, Rieders B, Todaro R. Primary gastric tuberculosis presenting as pyloric outlet obstruction. Am J Gastroenterol 1991; 86:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/59\">",
"      Cappell MS, Taunk JL. A chronic gastric ulcer refractory to conventional antiulcer therapy associated with localized gastric Mycobacterium avium intracellulare infection. Am J Gastroenterol 1991; 86:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/60\">",
"      Dees A, Batenburg PL, Umar HM, et al. Strongyloides stercoralis associated with a bleeding gastric ulcer. Gut 1990; 31:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/61\">",
"      Sharon P, Stalnikovicz R, Rachmilewitz D. Endoscopic diagnosis of duodenal neoplasms causing upper gastrointestinal bleeding. J Clin Gastroenterol 1982; 4:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/62\">",
"      Wald A, Milligan FD. The role of fiberoptic endoscopy in the diagnosis and management of duodenal neoplasms. Am J Dig Dis 1975; 20:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13609/abstract/63\">",
"      Grischkan D, Brown L, Mazansky H, et al. Localized duodenal lymphoma masquerading as a duodenal ulcer. Can J Surg 1982; 25:213.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 26 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13609=[""].join("\n");
var outline_f13_18_13609=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H930489\">",
"      Ulcer-like dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H930571\">",
"      Food-provoked dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4214164\">",
"      Other GI symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Silent ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H931262\">",
"      Predictive value of symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ulcer complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NSAID-induced ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Atypical ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Giant ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pyloric channel ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Postbulbar ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Multiple ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Gastric carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other neoplastic lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Drug-induced dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Infiltrative or granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Duodenal neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Associated diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/26\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/26|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/13/25823\" title=\"diagnostic image 1\">",
"      Crohns disease stomach UGI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/26|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/16/13583\" title=\"picture 1\">",
"      Multiple duodenal ulcers Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/32/17927\" title=\"picture 2\">",
"      Giardia lamblia Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/26|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/22/3436\" title=\"table 1\">",
"      Differential diagnosis of upper abdominal pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24919?source=related_link\">",
"      Diagnosis of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=related_link\">",
"      Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19113?source=related_link\">",
"      Epidemiology and etiology of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17638?source=related_link\">",
"      Gastrointestinal sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2984?source=related_link\">",
"      Large gastric folds: Hyperplastic and nonhyperplastic gastropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=related_link\">",
"      Overview of nontuberculous mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40282?source=related_link\">",
"      Overview of the complications of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/46/1763?source=related_link\">",
"      Patient information: Gastritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=related_link\">",
"      Patient information: H. pylori infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=related_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=related_link\">",
"      Patient information: Peptic ulcer disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=related_link\">",
"      Patient information: Peptic ulcers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=related_link\">",
"      Strongyloidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=related_link\">",
"      Unusual causes of peptic ulcer disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_18_13610="Pathophysiology, clinical features, and evaluation of mitral stenosis";
var content_f13_18_13610=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology, clinical features, and evaluation of mitral stenosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/18/13610/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/18/13610/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/18/13610/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/18/13610/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/18/13610/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/18/13610/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/18/13610/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral stenosis (MS), resulting from thickening and immobility of the mitral valve leaflets (",
"    <a class=\"graphic graphic_figure graphicRef79932 \" href=\"UTD.htm?5/22/5476\">",
"     figure 1",
"    </a>",
"    ), causes an obstruction in blood flow from the left atrium to left ventricle. As a result, there is an increase in pressure within the left atrium, pulmonary vasculature, and right side of the heart, while the left ventricle is unaffected in isolated MS. However, MS often coexists with mitral regurgitation and occasionally with aortic valve dysfunction, which may cause left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the etiology, pathophysiology, clinical features, and evaluation of MS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/2\">",
"     2",
"    </a>",
"    ]. Other issues related to MS . Other issues related to MS, such as the natural history, medical and surgical therapy, and use of percutaneous balloon valvotomy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/29/18901?source=see_link\">",
"     \"Natural history of mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4697?source=see_link\">",
"     \"Medical management and indications for intervention in mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=see_link\">",
"     \"Surgical management of mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=see_link\">",
"     \"Percutaneous mitral balloon valvotomy for mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rheumatic heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the great majority of cases, mitral stenosis is caused by rheumatic involvement of the mitral valve [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], although only 50 to 70 percent of patients report a history of rheumatic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. In a surgical pathology series of 452 patients with MS seen at the Mayo Clinic, for example, 99 percent had postinflammatory disease that was presumed to be rheumatic in origin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another report of 1051 consecutive patients who presented for surgical correction of mitral stenosis, the etiology was rheumatic in 77 percent and may have been higher if not for the 15 percent of cases in which the etiology was not classified [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/4\">",
"     4",
"    </a>",
"    ]. Infective endocarditis and mitral annular calcification accounted for 3.3 and 2.7 percent of cases, respectively. Other etiologies such as congenital malformation, systemic lupus erythematosus, carcinoid heart disease, endomyocardial fibrosis, and rheumatoid arthritis were implicated in less than 1 percent of cases.",
"   </p>",
"   <p>",
"    Rheumatic carditis as a cause of MS has become less common in developed countries given marked reductions in the incidence of rheumatic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/8\">",
"     8",
"    </a>",
"    ]. However, there are occasional outbreaks of rheumatic fever in the United States that result from either increased virulence of a streptococcal strain or enhanced immigration from areas where rheumatic heart disease is prevalent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/9\">",
"     9",
"    </a>",
"    ]. The majority of the world's population live in developing countries with high prevalence of rheumatic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=see_link\">",
"     \"Epidemiology and pathogenesis of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Development of MS after rheumatic fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carditis can occur in the acute form of rheumatic fever and can progress to rheumatic heart disease. The inflammatory process in the valve leaflets is thought to be initiated by cross-reactivity between streptococcal antigen and the valve tissue; there is no evidence for active infection of the valve leaflets. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=see_link\">",
"     \"Epidemiology and pathogenesis of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the incidence of rheumatic heart disease is variable after an episode of acute rheumatic fever, approximately 50 percent of those with evidence of carditis develop organic valvular damage. In addition, up to 75 percent of patients with documented recurrences of rheumatic fever have some form of valvular disease after 45 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rheumatic mitral stenosis has a delayed onset compared to rheumatic mitral regurgitation (MR), as illustrated by the followed observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an echocardiographic screening study of children aged 6 through 17 years old in Cambodia and Mozambique, the mitral valve was involved in 87 and 98 percent of detected cases or rheumatic heart disease; all were due to MR as there were no cases of MS [",
"      <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report of patients with surgically treated rheumatic mitral valve disease, most cases with pure MR occurred in those under 30 years of age while pure mitral stenosis and mixed mitral stenosis and regurgitation increased progressively over time with a peak prevalence over age 30 [",
"      <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In certain developing countries, the ineffective use of antibiotics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased virulence of the Streptococcus organism cause a more severe primary rheumatic insult [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/1\">",
"     1",
"    </a>",
"    ]. The ensuing acute inflammatory process can lead to commissural adhesion prior to the more common degenerative sequelae. It is therefore not uncommon in some of these countries to see symptomatic MS in patients less than 20 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/1,13\">",
"     1,13",
"    </a>",
"    ], compared to the typical development of symptoms between the ages of 30 and 50 in developed nations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/6\">",
"     6",
"    </a>",
"    ]. This phenomenon was illustrated by a review from Cameroon of 262 transthoracic echocardiograms performed to evaluate murmur in children (aged 5 to 18, mean age 10 years); 65 percent revealed rheumatic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/13\">",
"     13",
"    </a>",
"    ]. Of the 169 patients with rheumatic valve disease, the majority (60 percent) had pure mitral regurgitation, but mitral stenosis (pure mitral stenosis in 25 percent, and mixed mitral valve disease in 14 percent) were also common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Congenital MS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In countries that have a low prevalence of rheumatic valve disease, MS in nonimmigrant adolescents and young adults is often congenital [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/14\">",
"     14",
"    </a>",
"    ]. Multiple valve components are often involved, such as rolled, thickened leaflet margins, hypoplasia or fusion of the papillary muscles (including parachute mitral valve), and short and thickened chordae tendineae [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Accessory mitral valve tissue is a rare cause of congenital MS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/17\">",
"     17",
"    </a>",
"    ]. Affected patients may have a number of other congenital abnormalities involving the left side of the heart, including a bicuspid aortic valve and coarctation of the aorta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other disorders are infrequent causes or simulators of MS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitral annular calcification is a common disorder that rarely leads to mitral stenosis, particularly in patients with end-stage renal disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/59/954?source=see_link&amp;anchor=H21#H21\">",
"       \"Valvular heart disease in patients with end-stage renal disease\", section on 'Mitral stenosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A picture simulating mitral stenosis can result from obstruction of the mitral valve. This can occur with a left atrial myxoma or cor triatriatum, an uncommon congenital abnormality in which there is a membrane within the left atrium producing two left atrial chambers. The mitral valve itself is normal in these disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=see_link\">",
"       \"Cardiac tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with a prosthetic or tissue mitral valve, stenosis of the leaflet or prosthesis may result in the clinical picture of \"mitral stenosis\" and the symptoms are often rapid in onset. The valve dysfunction in this setting may result from acute or chronic thrombosis, pannus ingrowth on the atrial side of the valve, or leaflet calcification. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H8#H8\">",
"       \"Complications of prosthetic heart valves\", section on 'Valve obstruction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the mitral valve is present in approximately 90 percent of individuals with rheumatic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/18\">",
"     18",
"    </a>",
"    ]. Mitral disease begins with the formation of tiny nodules located along the coapting portions of the valve leaflets [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/6\">",
"     6",
"    </a>",
"    ]. The leaflets thicken with eventual deposition of fibrin on the cusps and loss of normal valve morphology.",
"   </p>",
"   <p>",
"    Disease progression results in a number of pathologic changes affecting the mitral valve apparatus, which are diagnostic for rheumatic valve disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fusion of the leaflet commissures",
"     </li>",
"     <li>",
"      Thickening, fusion and shortening of the chordae tendineae",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there may superimposed thickening, fibrosis, and calcification of the leaflet cusps [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/19\">",
"     19",
"    </a>",
"    ]. These degenerative changes often develop over the span of decades [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect is a stenotic mitral valve with a symmetric, central oval-shaped orifice and a classic pattern of \"doming\" of the leaflets in diastole due to fusion of the leaflet tips at the commissures. The degree of leaflet thickening and calcification and the severity of chordal involvement are variable.",
"   </p>",
"   <p>",
"    Commisural fusion and chordal shortening are due to recurrent rheumatic fever with repetitive valve scarring, but leaflet thickening and calcification appear to be primarily due to the stress of chronic turbulent flow through a deformed valve. Consistent with this hypothesis is the observation in a study from South Africa that ongoing rheumatic activity was present in 2 percent of patients with pure MS compared to 47 percent of patients with pure mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/29/18901?source=see_link\">",
"     \"Natural history of mitral stenosis\"",
"    </a>",
"    .) Also supportive of this hypothesis is the observation that recurrent stenosis after mitral valvuloplasty, without intervening episodes of rheumatic fever, is due to leaflet thickening and calcification without recurrent commisural fusion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardiac hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary hemodynamic consequence of MS is a pressure gradient between the left atrium and left ventricle in diastole. The elevated left atrial pressure is reflected backward, causing an increase in pulmonary venous, capillary, and arterial pressures and resistance. With mild to moderate MS, these abnormalities are often only apparent with exercise or other conditions that increase heart rate; they eventually are seen at rest as the severity of the stenosis increases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/29/18901?source=see_link\">",
"     \"Natural history of mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With isolated MS, the left ventricular systolic and diastolic pressures are usually normal. However, when the stenosis is very severe, there may be a decrease in left ventricular filling and end-diastolic volume (ie, preload), leading to reductions in stroke volume and cardiac output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=see_link\">",
"     \"Hemodynamics of valvular disorders as measured by cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hypertension is a common complication of MS. The elevation in pulmonary artery pressure can be divided into two components: the passive increase in pressure due to backward transmission of the elevated left atrial pressure; and reactive pulmonary vascular disease with sequential changes that include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary arterial and arteriolar vasoconstriction; this may be mediated, in part, by endothelium-dependent regulation of vascular tone since inhaled nitric oxide can acutely decrease pulmonary vascular resistance and pulmonary artery pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypertrophy of the pulmonary artery muscular layer",
"     </li>",
"     <li>",
"      Organic obliterative changes in the pulmonary vascular bed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link\">",
"     \"Pathogenesis of pulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary hypertension eventually leads to right ventricular hypertrophy and enlargement, tricuspid regurgitation, increased right atrial pressure, and the development of right-sided heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19\">",
"     'Right-sided heart failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The pulmonary hypertension in patients with MS is potentially completely reversible. This was illustrated in a randomized comparison of balloon valvuloplasty (valvotomy) and open surgical commissurotomy in patients with severe MS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/24\">",
"     24",
"    </a>",
"    ]. The pulmonary artery systolic pressure was approximately 55 mmHg at baseline and fell to 49 mmHg one week after the procedure and then to 32 mmHg at three-year follow-up (",
"    <a class=\"graphic graphic_figure graphicRef73230 \" href=\"UTD.htm?42/60/43981\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms induced by MS are primarily related to the severity of the valvular stenosis as reflected by the left atrial pressure, pulmonary pressures, pulmonary vascular resistance, and cardiac output. However, many patients with severe MS deny symptoms because slow progression of disease is \"matched\" by a gradual reduction in activity. As a result, a careful history regarding maximum levels of exertion is often required to document a slow decline in exercise tolerance.",
"   </p>",
"   <p>",
"    Any situation that increases the cardiac output, which raises transmitral flow, or causes tachycardia, which decreases diastolic filling time, can markedly increase the transmitral pressure gradient and precipitate symptoms such as dyspnea or hemoptysis, even in patients with mild MS. In some patients, the diagnosis of MS is first made when the patient is exposed to such stresses. Others present only with a secondary complication, such as AF or an embolic event.",
"   </p>",
"   <p>",
"    The clinical spectrum of MS is illustrated by a cross sectional study of 203 consecutive patients with mitral stenosis in Southern India, mean age was 53 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/25\">",
"     25",
"    </a>",
"    ]. The prevalence of atrial fibrillation, pulmonary edema, and stroke increased with age. However, the prevalence of pulmonary hypertension was 66 percent in those younger than age 40 years compared to 42 percent in older patients. Although symptom status and severity, left atrial size, and mitral stenosis severity were similar in all age groups, older patients were less likely to have mitral valve morphology favorable for balloon valvuloplasty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Time to clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interval between the episode of rheumatic fever and the clinical presentation of MS varies geographically, ranging from as little as a few years in countries with a high prevalence of rheumatic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/1\">",
"     1",
"    </a>",
"    ] to 20 years in countries where rheumatic fever is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. In a prospective study of 159 patients with MS from Germany, the following observations were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean interval between rheumatic fever and the onset of symptoms was 16.3 years.",
"     </li>",
"     <li>",
"      At 25 years after the initial episode of rheumatic fever, 8 percent were asymptomatic, 9 percent were New York Heart Association (NYHA) class II, 33 percent were NYHA class III, and 50 percent were NYHA class IV or had undergone mitral valve surgery (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Progression of mild to severe disability took an average of 9.2&plusmn;4.3 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As mentioned above, the more rapid progression in areas of high prevalence may be due to the ineffective use of antibiotics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased virulence of the Streptococcus organism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/29/18901?source=see_link\">",
"     \"Natural history of mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Relation to severity of MS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal mitral valve orifice has a cross sectional area of about 4.0 cm2. When the orifice is reduced to 2 cm2, mitral stenosis is mild and there is a small pressure gradient between the left atrium and ventricle (",
"    <a class=\"graphic graphic_table graphicRef56145 \" href=\"UTD.htm?25/20/25931\">",
"     table 2",
"    </a>",
"    ). Severe mitral stenosis is defined as an orifice area of &le;1.0 cm2 and is associated with a significant pressure gradient between the left atrium and left ventricle. However, patients with moderate stenosis (valve area 1.0 to 1.5 cm2) may have clinical symptoms or complications due to valve obstruction such as AF and pulmonary hypertension.",
"   </p>",
"   <p>",
"    Once MS is present, the average rate of hemodynamic progression is a decrease in valve area of about 0.1",
"    <span class=\"nowrap\">",
"     cm2/year",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Predictors of progression include a higher initial transmitral gradient and a more deformed and calcified valve [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dyspnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common and often only symptom of MS is dyspnea, which occurs in up to 70 percent of symptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/7\">",
"     7",
"    </a>",
"    ]. Dyspnea often results from the elevation in left atrial pressure, leading to reduced compliance of the lungs and a decrease in vital capacity due to vascular congestion and interstitial edema. Dyspnea also may be related to an inability to increase the cardiac output with increased metabolic demands.",
"   </p>",
"   <p>",
"    Dyspnea initially occurs with any condition that requires an increase in blood flow across the mitral valve or that reduces the time for such blood flow to occur (ie, diminishes the duration of diastole). These conditions include exertion, emotional stress, fever, pulmonary infection, sexual intercourse, AF, and pregnancy. Persistent shortness of breath, cough, and bronchitic symptoms are consistent with mild heart failure.",
"   </p>",
"   <p>",
"    As the degree of MS increases, dyspnea occurs with very little effort and orthopnea may also occur. A common complaint at this time is fatigue due to the reduction in cardiac output.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hemoptysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased pulmonary pressures and vascular congestion can lead to hemoptysis, which may have a variety of clinical manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sudden hemorrhage (pulmonary apoplexy) due to the rupture of thin walled and dilated bronchial veins when there is a sudden increase in left atrial pressure. This complication is rarely life-threatening, despite the large amount of bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link\">",
"       \"Massive hemoptysis: Initial management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blood tinged sputum induced by severe coughing associated with paroxysmal nocturnal dyspnea or bronchitis.",
"     </li>",
"     <li>",
"      Pink frothy sputum resulting from pulmonary edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11786166\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) is common in patients with MS due to the elevation of left atrial pressure and consequent left atrial enlargement. The prevalence of AF is higher with more severe disease, increasing age, and the presence of other valvular abnormalities. In a report that included 854 patients with MS, AF was present in 47 percent overall; the rate was higher in those with other valvular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 250 patients with isolated mitral stenosis &mdash; 29 percent",
"     </li>",
"     <li>",
"      Among the 274 patients with mitral stenosis and mitral regurgitation &mdash; 52 percent",
"     </li>",
"     <li>",
"      Among the 144 patients with MS, mitral regurgitation, and tricuspid regurgitation &mdash; 70 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On multivariate analysis, there were only two independent risk factors for AF: left atrial diameter and increasing age. Studies of patients with severe MS also found that the rate of AF varied importantly with patient age, ranging from 4 to 7 percent when the mean patient age was under 30 years to as high as 50 to 60 percent when the mean age was 50 to 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/20,29-31\">",
"     20,29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset of AF can lead to clinical decompensation via two mechanisms: the loss of atrial contraction, which plays an important role in the generation of adequate left atrial pressure to maintain blood flow across the stenotic valve; and the rapid ventricular response which, due to the reduction in the duration of diastole, diminishes the time available for filling of the left ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link\">",
"     \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not infrequently, the first presentation of MS is an embolic event, most commonly cerebral. Prior to surgical treatment and the widespread use of anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , as many as 30 percent of patients with MS experienced an embolic event during the course of the disease.",
"   </p>",
"   <p>",
"    Various studies have found that predictors of embolism in patients with MS include presence of AF as well as low or reduced cardiac output, and size of the left atrium and its appendage. Over 80 percent of patients with MS who have an embolism are in AF. A study of 260 patients with MS found that atrial fibrillation was the main independent predictor of left atrial thrombus (OR 5.95, 95% CI 1.2-29.3); estimated right ventricular systolic pressure was also a significant predictor although its impact was slight (OR 1.02, 95% CI 1.01-1.04) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients in AF, previous embolism is a predictor of increased risk (relative risk 3.1), while early percutaneous balloon mitral commissurotomy prevents systemic embolism in patients with and without AF [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=see_link\">",
"     \"Percutaneous mitral balloon valvotomy for mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The predictors of embolic events in patients with MS who are in sinus rhythm were assessed in a study that included 132 such patients who had a valve area less than 2 cm2 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/34\">",
"     34",
"    </a>",
"    ]. There were three major clinical and echocardiographic predictors of embolism:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Left atrial thrombus (relative risk 37)",
"     </li>",
"     <li>",
"      The degree of reduction in mitral valve area (relative risk 16.9)",
"     </li>",
"     <li>",
"      Significant aortic regurgitation (relative risk 22.4)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transient AF and infective endocarditis should also be considered when embolization occurs in patients with mitral stenosis who are in sinus rhythm.",
"   </p>",
"   <p>",
"    A transesophageal echocardiographic study of 848 patients with moderate to severe MS in sinus rhythm found left atrial thrombus in 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients with MS in normal sinus rhythm have decreased atrial contractile function, which can lead to spontaneous contrast (SEC) on transesophageal echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. SEC is a marker of blood flow stasis and is associated with an increased risk of left atrial thrombus and embolic events in patients with AF, although it was not found to be an independent predictor of left atrial thrombus in patients in sinus rhythm and MS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most emboli originate from the left atrium (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=see_link\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\"",
"    </a>",
"    ). The most common site for clinically evident embolism is the cerebral circulation, but any organ may be involved, especially spleen, kidneys, and the coronary circulation, resulting in a myocardial infarction. Emboli can also arise from the right atrium when there is pulmonary hypertension and right ventricular and atrial dilatation. Emboli from this site lead to pulmonary embolism and infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MS infrequently experience chest pain. Although the pain often resembles angina and may be due to underlying coronary artery disease or a coronary artery embolism, it is most commonly the result of pulmonary hypertension and right ventricular hypertrophy. Another cause of intermittent chest pain is an atrial tachyarrhythmia with left atrial and pulmonary vascular distension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=see_link\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Infective endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the mitral valve is deformed, there is the potential for infective endocarditis (IE). This complication is primarily associated with mild mitral stenosis when the valve is stiff and fibrotic. Endocarditis is uncommon once the valve becomes calcified and very rigid.",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis against endocarditis is NOT recommended in patients with native valve mitral stenosis in the absence of prosthetic replacement (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Right-sided heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pulmonary hypertension eventually leads to increased right ventricular and right atrial pressures, right ventricular enlargement, tricuspid regurgitation, and signs of right-sided heart failure. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Pulmonary hypertension'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis of pulmonary hypertension\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs of right-sided heart failure include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased jugular venous pressure (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"       \"Examination of the jugular venous pulse\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Edema of both legs, which may progress to involve the upper thighs, sacral area, and abdominal wall; ascites and pleural effusions can also occur.",
"     </li>",
"     <li>",
"      Hepatomegaly in which the liver may be pulsatile if tricuspid regurgitation is present",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hoarseness",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the left atrium becomes very large, there may be compression of the recurrent laryngeal nerve leading to hoarseness (Ortner's syndrome or cardiovocal syndrome) or coughing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16009?source=see_link\">",
"     \"Hoarseness in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Effect of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in heart rate and cardiac output during pregnancy can substantially increase the resting transmitral gradient in women with mitral stenosis, which can lead to symptoms in a previously asymptomatic (and perhaps undiagnosed) patient or an exacerbation of symptoms in an already symptomatic patient. Medical management and, if this fails, percutaneous mitral balloon valvotomy are the mainstays of therapy. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29447?source=see_link\">",
"     \"Pregnancy in women with mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=see_link&amp;anchor=H17#H17\">",
"     \"Percutaneous mitral balloon valvotomy for mitral stenosis\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination, especially examination of the arterial and venous pulses and the heart, can be diagnostic for mitral stenosis. However, except for severe long-standing disease, the physical findings are subtle and the murmur may be difficult to appreciate. As a result, the diagnosis is mostly based upon the clinical history (symptoms in a patient with typical demographics) and confirmed by echocardiography.",
"   </p>",
"   <p>",
"    Other than the auscultation findings, which are discussed below, the classic physical findings of MS include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The arterial pulses are reduced in volume due to the decreased stroke volume. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=see_link\">",
"       \"Examination of the arterial pulse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When MS is severe and the cardiac output is diminished, there is vasoconstriction, resulting in pinkish-purple patches on the cheeks (mitral facies).",
"     </li>",
"     <li>",
"      Pulmonary hypertension and right ventricular hypertrophy can lead to a prominent \"a\" wave (atrial contraction or systole) in jugular venous pulsations, reflecting elevated right atrial pressure. The \"a\" wave is absent in patients with AF and only a prominent \"v\" wave (atrial filling during ventricular systole when the tricuspid valve is closed) is seen. If present, tricuspid regurgitation can lead to a prominent \"c-v\" wave (reflecting regurgitation of blood into the right atrium) and the neck veins are very pulsatile. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"       \"Examination of the jugular venous pulse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Palpation and percussion of the chest wall reveals an apical impulse that is generally normal, although it may be reduced in intensity, reflecting the decreased left ventricular filling. However, if pulmonary hypertension is present, there may be a right ventricular heave (substernal lift) and a palpable S2. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=see_link\">",
"       \"Examination of the precordial pulsation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Advanced disease may be associated with the signs of right-sided heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cardiac auscultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac auscultation may be diagnostic for MS with careful patient positioning in a quiet room. However, the murmur may be difficult to appreciate, particularly when MS presents during pregnancy or with rapid AF. The following findings are characteristic for MS, but their absence does not exclude the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Heart sounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a result of the elevated left atrial pressure, the stenotic (but noncalcified) mitral leaflets are still widely separated at the onset of ventricular contraction. Thus, the first heart sound (S1) is loud, reflecting the increased excursion of the leaflets (",
"    <a class=\"graphic graphic_movie graphicRef55136 \" href=\"UTD.htm?7/25/7571\">",
"     movie 1",
"    </a>",
"    ). As the leaflets become more rigid and calcified, their motion is limited and S1 becomes soft. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The second heart sound is initially normal but, with the development of pulmonary hypertension, P2 becomes increased in intensity and may be widely transmitted. As pressure increases further, splitting of S2 is reduced and ultimately S2 becomes a single sound.",
"   </p>",
"   <p>",
"    A third heart sound of left ventricular origin is",
"    <strong>",
"     never",
"    </strong>",
"    heard in pure MS because of the obstruction to flow across the mitral valve. However, it may be present if there is coexisting aortic or mitral regurgitation or may be generated from the right ventricle.",
"   </p>",
"   <p>",
"    A fourth heart sound may be heard, most often originating from the right ventricle when it is hypertrophied and dilated and the patient is still in sinus rhythm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Opening snap",
"    </span>",
"    &nbsp;&mdash;&nbsp;An opening snap (OS) of the mitral valve is heard at the apex when the leaflets are still mobile (",
"    <a class=\"graphic graphic_movie graphicRef55136 \" href=\"UTD.htm?7/25/7571\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef66921 \" href=\"UTD.htm?28/24/29057\">",
"     movie 2",
"    </a>",
"    ). The OS is due to the abrupt halt in leaflet motion in early diastole, after rapid initial rapid opening, due to fusion at the leaflet tips. It is best heard at the apex and lower left sternal border. The OS following S2 may be mistaken for a split S2 unless the examiner recognizes that the OS is best appreciated at the apex, not the base. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As the MS progresses and left atrial pressure is higher, the OS occurs earlier after S2 or A2. Thus, the shorter the A2-OS interval, the more severe the mitral stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Diastolic murmur",
"    </span>",
"    &nbsp;&mdash;&nbsp;The murmur caused by MS is a low-pitched diastolic rumble that is most prominent at the apex. It is heard best in a quiet room with the patient lying on the left side in held expiration and by using the bell of the stethoscope or the low frequency range of an electronic stethoscope (",
"    <a class=\"graphic graphic_movie graphicRef55136 \" href=\"UTD.htm?7/25/7571\">",
"     movie 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although the intensity of the diastolic murmur does not correlate with the severity of the stenosis, the duration of the murmur is helpful since it reflects the transvalvular gradient and the duration of blood flow across the valve.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When MS is mild, the gradient is confined to atrial systole and hence the murmur is heard late in diastole, just before S1.",
"     </li>",
"     <li>",
"      As the stenosis becomes more severe, there is a gradient at the very onset of the diastolic flow period, immediately following the OS. This early diastolic murmur is decrescendo, becoming softer as the left atrial pressure falls and the transvalvular gradient decreases. If the patient is still in sinus rhythm, the increase in atrial pressure after atrial contraction, results in an increase in the loudness of the murmur, termed \"presystolic accentuation\" (",
"      <a class=\"graphic graphic_movie graphicRef55136 \" href=\"UTD.htm?7/25/7571\">",
"       movie 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      With more severe MS, there is a continuous gradient throughout all of the diastolic flow period, from mitral valve opening to mitral valve closure. The diastolic murmur may be inaudible or absent when MS is very severe, due to the very slow flow across the mitral valve. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"       \"Auscultation of cardiac murmurs\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several maneuvers that have been used in the past for evaluation of heart sounds in MS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41876?source=see_link\">",
"     \"Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diastolic murmur and OS are diminished with inspiration, but augmented with expiration (in contrast to tricuspid stenosis). With inspiration, the A2-OS interval widens and a distinct P2 may be heard.",
"     </li>",
"     <li>",
"      Increasing venous return, eg, by lying the patient down and lifting the legs, augments the gradient; as a result, the diastolic murmur lengthens while the A2-OS intervals shorten. Similar changes are seen in response to exercise. In contrast, reducing venous return with amyl nitrate, the Valsalva maneuver, or standing after squatting shortens the murmur and lengthens the A2-OS interval.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are other murmurs or sounds that may be heard in patients with MS, particularly when pulmonary hypertension is present.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pulmonary ejection sound, which diminishes with inspiration when the pulmonary arteries dilate.",
"     </li>",
"     <li>",
"      With the development of tricuspid regurgitation, there is a holosystolic murmur best heard along the right sternal border which increases with inspiration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/9/149?source=see_link\">",
"       \"Etiology, clinical features, and evaluation of tricuspid regurgitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A faint and brief murmur of pulmonic regurgitation (Graham Steell murmur) may be heard at the base. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link&amp;anchor=H38#H38\">",
"       \"Auscultation of cardiac murmurs\", section on 'Pulmonic regurgitation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Murmurs of mitral or aortic regurgitation may also be present if these valve lesions coexist with MS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of tests can help to document the presence and assess the severity of MS. The most important is echocardiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of patients with valvular heart disease included recommendations for the use of echocardiography in patients with asymptomatic and symptomatic murmurs (",
"    <a class=\"graphic graphic_table graphicRef50108 graphicRef58419 \" href=\"UTD.htm?39/46/40684\">",
"     table 3A-B",
"    </a>",
"    ) and the use of echocardiography, transesophageal echocardiography, and cardiac catheterization in patients with mitral stenosis (",
"    <a class=\"graphic graphic_table graphicRef68079 graphicRef52663 graphicRef68069 \" href=\"UTD.htm?31/55/32637\">",
"     table 4A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Echocardiographic imaging provides determination of the etiology of stenosis, evaluation of the detailed morphology of the valve apparatus, measurement of valve orifice, and evaluation of subvalvular structures, particularly the chordae and papillary muscles. Doppler echocardiography provides accurate assessment of the transvalvular gradient and valve area. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=see_link\">",
"     \"Echocardiographic evaluation of the mitral valve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42040?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of mitral valve disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to its use in initial evaluation, echocardiography is performed serially in asymptomatic stable patients to assess progression of the valve disease and is an essential screening procedure in patients who appear to be candidates for percutaneous mitral balloon valvotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=see_link&amp;anchor=H6#H6\">",
"     \"Percutaneous mitral balloon valvotomy for mitral stenosis\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Transthoracic",
"    </span>",
"    &nbsp;&mdash;&nbsp;With transthoracic two-dimensional (2-D) echocardiography, the mitral leaflets are thickened, have reduced motion during diastole, and show doming, which is indicative of commissural fusion (",
"    <a class=\"graphic graphic_movie graphicRef62748 \" href=\"UTD.htm?18/60/19393\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef58100 \" href=\"UTD.htm?20/25/20884\">",
"     movie 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef71501 \" href=\"UTD.htm?7/49/7957\">",
"     movie 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef78565 \" href=\"UTD.htm?3/0/3074\">",
"     movie 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef76132 \" href=\"UTD.htm?19/32/19972\">",
"     movie 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, the following parameters can be determined:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mitral valve area can be accurately measured by planimetry in short axis views.",
"     </li>",
"     <li>",
"      Estimates of leaflet motion, the degree of calcification and fibrosis of the leaflets, and assessment of the subvalvular apparatus can help establish the role for surgical or balloon valvotomy. Other aspects of mitral valve morphology that are used in decisions about valvuloplasty include the degree and symmetry of commissural fusion and calcification and the irregularity of valve calcification. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=see_link\">",
"       \"Percutaneous mitral balloon valvotomy for mitral stenosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=see_link\">",
"       \"Surgical management of mitral stenosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Left atrial size, and left and right ventricular size and systolic function can be assessed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When evaluation for left atrial thrombus is needed, transesophageal echocardiography should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler echocardiography provides an accurate assessment of the hemodynamic effects of the stenosis. The mean transvalvular gradient and the pressure half-time valve area can be accurately calculated from the diastolic velocity curve (",
"    <a class=\"graphic graphic_movie graphicRef52554 \" href=\"UTD.htm?29/43/30399\">",
"     movie 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef56331 \" href=\"UTD.htm?40/15/41215\">",
"     waveform 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pulsed, continuous wave, and color Doppler are used to evaluate coexisting mitral regurgitation. Pulmonary pressures are calculated from the velocity of the tricuspid regurgitation jet and right atrial pressure, which is estimated from the size and respiratory variation in the inferior vena cava.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Three-dimensional",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard two-dimensional (2-D) and Doppler echocardiography are adequate for the evaluation of MS in almost all cases, but three-dimensional echocardiography (3-D echo) has also been studied [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. This technique can provide an en-face cross sectional view of the mitral orifice, to which planimetry can be applied to accurately determine the valve area. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23146?source=see_link&amp;anchor=H11#H11\">",
"     \"Three-dimensional echocardiography\", section on 'Mitral valve'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38067909\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings on the surface ECG reflect the hemodynamic alterations that are present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The QRS amplitude and morphology are normal unless there is mitral regurgitation or coexistent aortic valve disease.",
"     </li>",
"     <li>",
"      Left atrial hypertrophy and enlargement results in a P wave that becomes broader (duration in lead II&gt;0.12 sec), is of increased amplitude, and is notched (due to the delay in left atrial activation). This is termed \"P-mitrale.\" The left atrial changes also produce a prominent negative terminal portion of the P wave in lead V1.",
"     </li>",
"     <li>",
"      The P waves changes are not seen in patients with atrial fibrillation. The fibrillatory waves are coarse, generally &gt;0.1 mV in amplitude, reflecting left atrial hypertrophy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional changes occur with the development of pulmonary hypertension and right ventricular hypertrophy. The frontal axis shifts to the right (S&gt;R in lead I and aVL) and a tall R wave develops in V1 and V2 (R&gt;S or",
"    <span class=\"nowrap\">",
"     R/S",
"    </span>",
"    ratio &gt;1).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38067916\">",
"    <span class=\"h2\">",
"     Chest x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest x-ray in mild mitral stenosis may be normal, although there is often evidence of some enlargement of the left atrium and appendage. Left atrial enlargement may produce a \"double density,\" the left heart border becomes straightened, the left bronchus is elevated, and, on the lateral projection, the left atrium is displaced posteriorly, impinging on the esophagus (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57247 \" href=\"UTD.htm?10/17/10514\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The size of the left atrium reflects the duration of severe MS. Younger patients with severe mitral stenosis may have only mild left atrial enlargement, while marked enlargement is typical in older patients. Left atrial size may be greater in patients with combined mitral stenosis and regurgitation.",
"   </p>",
"   <p>",
"    Other findings that may be seen include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcification of the annulus may be observed on an overpenetrated film in elderly patients with calcific mitral valve disease.",
"     </li>",
"     <li>",
"      Enlargement of the main pulmonary artery due to pulmonary hypertension, while the aorta and left ventricle are often small.",
"     </li>",
"     <li>",
"      Pulmonary vascular congestion with redistribution or \"cephalization\" of pulmonary blood flow to the upper lobes, dilated pulmonary vessels, Kerley B lines at the bases, and interlobar effusions (Kerley C lines) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57006 \" href=\"UTD.htm?16/21/16720\">",
"       image 2",
"      </a>",
"      ). In more severe cases, Kerley A lines (straight dense lines running toward the hilum) may be seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Stress echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise stress echocardiography can provide the following information in patients with MS:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An objective evaluation of exercise capacity",
"     </li>",
"     <li>",
"      Provocation of symptoms in inactive patients",
"     </li>",
"     <li>",
"      Measurement of pulmonary pressures with exercise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Exercise or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography is particularly helpful when symptoms seem to be more severe than expected based on resting hemodynamics (such as resting valve area); these patients often have exertional pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition to criteria based upon resting hemodynamics, mechanical relief of MS is recommended in patients with elevated pulmonary pressures (&gt;60 mmHg systolic) with exertion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=see_link\">",
"     \"Percutaneous mitral balloon valvotomy for mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=see_link\">",
"     \"Surgical management of mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35319?source=see_link&amp;anchor=H17#H17\">",
"     \"Protocols for stress echocardiography\", section on 'Mitral stenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exercise has the advantage of being the activity that usually precipitates the patient's symptoms. On the other hand,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress may be easier to use with echocardiography because it avoids the marked increase in respiration and chest movement that occur with exercise and that can make imaging more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=see_link&amp;anchor=H11#H11\">",
"     \"Echocardiographic evaluation of the mitral valve\", section on 'Stress echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other findings on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography may identify patients with MS who are likely to require corrective therapy. This was illustrated in a study of 53 patients with known MS who underwent dobutamine stress echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/41\">",
"     41",
"    </a>",
"    ]. The diastolic mitral gradient with dobutamine was a significant predictor of clinical events (arrhythmias or hospitalization for dyspnea or pulmonary edema), especially in patients with moderate disease (mitral valve area of 1.0 to 1.5 cm2) who were in New York Heart Association class I or II [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/40\">",
"     40",
"    </a>",
"    ]. At a cutoff gradient of 18 mmHg, dobutamine stress had a sensitivity of 90 percent and a specificity of 87 percent for predicting clinical events. However, the value of identifying patients with mild to moderate disease who might develop symptoms in the future is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Cardiac magnetic resonance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited on the use of cardiac magnetic resonance (CMR) imaging. In two series of 39 patients with mitral stenosis, the correlation coefficient of mitral valve area estimated by planimetry on CMR was 0.81 to 0.86 compared to Doppler pressure half-time echocardiography and 0.89 compared to catheterization Gorlin valve area [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. CMR slightly overestimates mitral valve area compared to echocardiography (by 8 percent) and catheterization (by 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/43\">",
"     43",
"    </a>",
"    ]. Thus, a CMR mitral valve area determined by planimetry of less than 1.65 cm2 suggests mitral stenosis as defined by a catheterization value of 1.5 cm2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H32#H32\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Valvular heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Currently CMR is not recommended for clinical evaluation of mitral stenosis and transthoracic echocardiography remains the clinical standard for the evaluation of the severity of MS due to its accuracy, widespread availability, and lower cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Cardiac catheterization and angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac catheterization and direct measurement of intracardiac pressures permit a precise determination of the gradient across the mitral valve and the severity of mitral stenosis (",
"    <a class=\"graphic graphic_waveform graphicRef52342 \" href=\"UTD.htm?14/42/15008\">",
"     waveform 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef61038 \" href=\"UTD.htm?12/24/12672\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=see_link\">",
"     \"Hemodynamics of valvular disorders as measured by cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The widespread availability of echocardiography has led to a limited role for cardiac catheterization in the diagnosis of MS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/14\">",
"     14",
"    </a>",
"    ]. However, invasive pressure measurements are warranted if noninvasive tests are not conclusive, there is a discrepancy between noninvasive tests and clinical findings or between clinical symptoms and hemodynamics at rest, or severe pulmonary arterial hypertension is out of proportion to the severity of MS as determined by noninvasive tests (",
"    <a class=\"graphic graphic_table graphicRef68069 \" href=\"UTD.htm?3/58/4012\">",
"     table 4C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/18/13610/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, invasive measurements are used, along with echocardiography, to monitor hemodynamics during a balloon mitral valvuloplasty procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=see_link\">",
"     \"Percutaneous mitral balloon valvotomy for mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/31/12787?source=see_link\">",
"       \"Patient information: Mitral stenosis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24817810\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the great majority of cases, mitral stenosis is caused by rheumatic involvement of the mitral valve. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Rheumatic heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disease progression results in a number of pathologic changes affecting the mitral valve apparatus, which are diagnostic for rheumatic valve disease: fusion of the leaflet commissures and thickening, fusion and shortening of the chordae tendineae. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common and often only symptom of MS is dyspnea, which occurs in up to 70 percent of symptomatic patients. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Dyspnea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various studies have found that predictors of embolism in patients with MS are cardiac output, size of the left atrium and its appendage, and the presence of AF. Over 80 percent of patients with MS who have an embolism are in AF. Among patients in AF, previous embolism is a predictor of increased risk (relative risk 3.1). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Thromboembolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The increase in heart rate and cardiac output during pregnancy can substantially increase the resting transmitral gradient in women with mitral stenosis, which can lead to symptoms in a previously asymptomatic (and perhaps undiagnosed) patient or an exacerbation of symptoms in an already symptomatic patient. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Effect of pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The murmur caused by MS is a low-pitched diastolic rumble that is most prominent at the apex. The murmur can be difficult to appreciate so an echocardiogram is appropriate if the clinical picture is suggestive of MS (eg, pregnant woman with heart failure) even if no murmur is heard. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Diastolic murmur'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echocardiographic imaging provides determination of the etiology of stenosis, evaluation of the detailed morphology of the valve apparatus, measurement of valve orifice, and evaluation of subvalvular structures, particularly the chordae and papillary muscles. Doppler echocardiography provides accurate assessment of the transvalvular gradient and valve area. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/1\">",
"      Marcus RH, Sareli P, Pocock WA, Barlow JB. The spectrum of severe rheumatic mitral valve disease in a developing country. Correlations among clinical presentation, surgical pathologic findings, and hemodynamic sequelae. Ann Intern Med 1994; 120:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/2\">",
"      Chandrashekhar Y, Westaby S, Narula J. Mitral stenosis. Lancet 2009; 374:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/3\">",
"      Olson LJ, Subramanian R, Ackermann DM, et al. Surgical pathology of the mitral valve: a study of 712 cases spanning 21 years. Mayo Clin Proc 1987; 62:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/4\">",
"      Horstkotte D, Niehues R, Strauer BE. Pathomorphological aspects, aetiology and natural history of acquired mitral valve stenosis. Eur Heart J 1991; 12 Suppl B:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/5\">",
"      WOOD P. An appreciation of mitral stenosis. I. Clinical features. Br Med J 1954; 1:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/6\">",
"      Selzer A, Cohn KE. Natural history of mitral stenosis: a review. Circulation 1972; 45:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/7\">",
"      ROWE JC, BLAND EF, SPRAGUE HB, WHITE PD. The course of mitral stenosis without surgery: ten- and twenty-year perspectives. Ann Intern Med 1960; 52:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/8\">",
"      Gordis L. The virtual disappearance of rheumatic fever in the United States: lessons in the rise and fall of disease. T. Duckett Jones memorial lecture. Circulation 1985; 72:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/9\">",
"      Feldman T. Rheumatic mitral stenosis. On the rise again. Postgrad Med 1993; 93:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/10\">",
"      Rheumatic fever and rheumatic heart disease. World Health Organ Tech Rep Ser 2004; 923:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/11\">",
"      Sani MU, Karaye KM, Borodo MM. Prevalence and pattern of rheumatic heart disease in the Nigerian savannah: an echocardiographic study. Cardiovasc J Afr 2007; 18:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/12\">",
"      Marijon E, Ou P, Celermajer DS, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 2007; 357:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/13\">",
"      Tantchou Tchoumi JC, Butera G. Rheumatic valvulopathies occurence, pattern and follow-up in rural area: the experience of the Shisong Hospital, Cameroon. Bull Soc Pathol Exot 2009; 102:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/14\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/15\">",
"      Ruckman RN, Van Praagh R. Anatomic types of congenital mitral stenosis: report of 49 autopsy cases with consideration of diagnosis and surgical implications. Am J Cardiol 1978; 42:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/16\">",
"      Moore P, Adatia I, Spevak PJ, et al. Severe congenital mitral stenosis in infants. Circulation 1994; 89:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/17\">",
"      Rao N, Gajjar T, Desai N. Accessory mitral valve tissue: an unusual cause of congenital mitral stenosis. Interact Cardiovasc Thorac Surg 2012; 14:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/18\">",
"      BLAND EF, DUCKETT JONES T. Rheumatic fever and rheumatic heart disease; a twenty year report on 1000 patients followed since childhood. Circulation 1951; 4:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/19\">",
"      Rajamannan NM, Nealis TB, Subramaniam M, et al. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation 2005; 111:3296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/20\">",
"      Hernandez R, Ba&ntilde;uelos C, Alfonso F, et al. Long-term clinical and echocardiographic follow-up after percutaneous mitral valvuloplasty with the Inoue balloon. Circulation 1999; 99:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/21\">",
"      Wang A, Krasuski RA, Warner JJ, et al. Serial echocardiographic evaluation of restenosis after successful percutaneous mitral commissurotomy. J Am Coll Cardiol 2002; 39:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/22\">",
"      Chen CR, Cheng TO. Percutaneous balloon mitral valvuloplasty by the Inoue technique: a multicenter study of 4832 patients in China. Am Heart J 1995; 129:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/23\">",
"      Mahoney PD, Loh E, Blitz LR, Herrmann HC. Hemodynamic effects of inhaled nitric oxide in women with mitral stenosis and pulmonary hypertension. Am J Cardiol 2001; 87:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/24\">",
"      Reyes VP, Raju BS, Wynne J, et al. Percutaneous balloon valvuloplasty compared with open surgical commissurotomy for mitral stenosis. N Engl J Med 1994; 331:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/25\">",
"      Ramakrishna CD, Khadar SA, George R, et al. The age-specific clinical and anatomical profile of mitral stenosis. Singapore Med J 2009; 50:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/26\">",
"      Gordon SP, Douglas PS, Come PC, Manning WJ. Two-dimensional and Doppler echocardiographic determinants of the natural history of mitral valve narrowing in patients with rheumatic mitral stenosis: implications for follow-up. J Am Coll Cardiol 1992; 19:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/27\">",
"      Sagie A, Freitas N, Padial LR, et al. Doppler echocardiographic assessment of long-term progression of mitral stenosis in 103 patients: valve area and right heart disease. J Am Coll Cardiol 1996; 28:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/28\">",
"      Diker E, Aydogdu S, Ozdemir M, et al. Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease. Am J Cardiol 1996; 77:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/29\">",
"      Arora R, Kalra GS, Murty GS, et al. Percutaneous transatrial mitral commissurotomy: immediate and intermediate results. J Am Coll Cardiol 1994; 23:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/30\">",
"      R&ouml;thlisberger C, Essop MR, Skudicky D, et al. Results of percutaneous balloon mitral valvotomy in young adults. Am J Cardiol 1993; 72:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/31\">",
"      Orrange SE, Kawanishi DT, Lopez BM, et al. Actuarial outcome after catheter balloon commissurotomy in patients with mitral stenosis. Circulation 1997; 95:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/32\">",
"      Nicod P, Hillis LD, Winniford MD, Firth BG. Importance of the \"atrial kick\" in determining the effective mitral valve orifice area in mitral stenosis. Am J Cardiol 1986; 57:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/33\">",
"      Boonyasirinant T, Phankinthongkum R, Komoltri C. Clinical and echocardiographic parameters and score for the left atrial thrombus formation prediction in the patients with mitral stenosis. J Med Assoc Thai 2007; 90 Suppl 2:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/34\">",
"      Chiang CW, Lo SK, Ko YS, et al. Predictors of systemic embolism in patients with mitral stenosis. A prospective study. Ann Intern Med 1998; 128:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/35\">",
"      Manjunath CN, Srinivasa KH, Panneerselvam A, et al. Incidence and predictors of left atrial thrombus in patients with rheumatic mitral stenosis and sinus rhythm: a transesophageal echocardiographic study. Echocardiography 2011; 28:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/36\">",
"      Rittoo D, Sutherland GR, Currie P, et al. A prospective study of left atrial spontaneous echo contrast and thrombus in 100 consecutive patients referred for balloon dilation of the mitral valve. J Am Soc Echocardiogr 1994; 7:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/37\">",
"      Goswami KC, Yadav R, Bahl VK. Predictors of left atrial appendage clot: a transesophageal echocardiographic study of left atrial appendage function in patients with severe mitral stenosis. Indian Heart J 2004; 56:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/38\">",
"      Dreyfus J, Brochet E, Lepage L, et al. Real-time 3D transoesophageal measurement of the mitral valve area in patients with mitral stenosis. Eur J Echocardiogr 2011; 12:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/39\">",
"      Schlosshan D, Aggarwal G, Mathur G, et al. Real-time 3D transesophageal echocardiography for the evaluation of rheumatic mitral stenosis. JACC Cardiovasc Imaging 2011; 4:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/40\">",
"      Picano E, Pibarot P, Lancellotti P, et al. The emerging role of exercise testing and stress echocardiography in valvular heart disease. J Am Coll Cardiol 2009; 54:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/41\">",
"      Brochet E, D&eacute;taint D, Fondard O, et al. Early hemodynamic changes versus peak values: what is more useful to predict occurrence of dyspnea during stress echocardiography in patients with asymptomatic mitral stenosis? J Am Soc Echocardiogr 2011; 24:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/42\">",
"      Lin SJ, Brown PA, Watkins MP, et al. Quantification of stenotic mitral valve area with magnetic resonance imaging and comparison with Doppler ultrasound. J Am Coll Cardiol 2004; 44:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/18/13610/abstract/43\">",
"      Djavidani B, Debl K, Lenhart M, et al. Planimetry of mitral valve stenosis by magnetic resonance imaging. J Am Coll Cardiol 2005; 45:2048.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8173 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-519069B3B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13610=[""].join("\n");
var outline_f13_18_13610=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24817810\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rheumatic heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Development of MS after rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Congenital MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardiac hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Time to clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Relation to severity of MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dyspnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hemoptysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11786166\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Right-sided heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hoarseness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Effect of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cardiac auscultation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Heart sounds",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Opening snap",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Diastolic murmur",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Transthoracic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Doppler",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Three-dimensional",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38067909\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38067916\">",
"      Chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Cardiac magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Cardiac catheterization and angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24817810\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8173\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8173|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/17/10514\" title=\"diagnostic image 1\">",
"      Mitral stenosis barium swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/21/16720\" title=\"diagnostic image 2\">",
"      Pulmonary hypertension MS angio",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8173|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/22/5476\" title=\"figure 1\">",
"      Mitral valve structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/60/43981\" title=\"figure 2\">",
"      PAH reversal in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/24/12672\" title=\"figure 3\">",
"      Pressures mitral stenosis II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8173|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?7/25/7571\" title=\"movie 1\">",
"      Mitral stenosis as heard at the apex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?28/24/29057\" title=\"movie 2\">",
"      Mitral stenosis as heard at the base",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?18/60/19393\" title=\"movie 3\">",
"      Mitral stenosis apical long axis echocardiogram 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?20/25/20884\" title=\"movie 4\">",
"      Mitral stenosis PLAX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?7/49/7957\" title=\"movie 5\">",
"      Mitral stenosis 4 chamber view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?3/0/3074\" title=\"movie 6\">",
"      Mitral stenosis apical long axis echocardiogram 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?19/32/19972\" title=\"movie 7\">",
"      Mitral stenosis parasternal long axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?29/43/30399\" title=\"movie 8\">",
"      Mitral stenosis apical long axis color Doppler echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8173|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/20/25931\" title=\"table 2\">",
"      Severity of MS in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/4/36939\" title=\"table 3A\">",
"      Echo asymptomatic murmurs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/35/17979\" title=\"table 3B\">",
"      Echo symptomatic murmurs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/25/40347\" title=\"table 4A\">",
"      Echo in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/42/22187\" title=\"table 4B\">",
"      TEE in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/58/4012\" title=\"table 4C\">",
"      Catheterization mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8173|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?40/15/41215\" title=\"waveform 1\">",
"      MS pulsed wave Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?14/42/15008\" title=\"waveform 2\">",
"      Pressures mitral stenosis I",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=related_link\">",
"      Echocardiographic evaluation of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=related_link\">",
"      Epidemiology and pathogenesis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/9/149?source=related_link\">",
"      Etiology, clinical features, and evaluation of tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=related_link\">",
"      Examination of the precordial pulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16009?source=related_link\">",
"      Hoarseness in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4697?source=related_link\">",
"      Medical management and indications for intervention in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/29/18901?source=related_link\">",
"      Natural history of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=related_link\">",
"      Pathogenesis of pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=related_link\">",
"      Pathophysiology and clinical presentation of ischemic chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/31/12787?source=related_link\">",
"      Patient information: Mitral stenosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=related_link\">",
"      Percutaneous mitral balloon valvotomy for mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41876?source=related_link\">",
"      Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29447?source=related_link\">",
"      Pregnancy in women with mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35319?source=related_link\">",
"      Protocols for stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=related_link\">",
"      Surgical management of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23146?source=related_link\">",
"      Three-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42040?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of mitral valve disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/59/954?source=related_link\">",
"      Valvular heart disease in patients with end-stage renal disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_18_13611="Patient selection for noninvasive ventilation";
var content_f13_18_13611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for selecting patients with chronic respiratory failure for noninvasive nocturnal ventilation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Chronic hypoventilation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Daytime PaCO2 &ge;45 mmHg",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Nocturnal hypoventilation with sustained O2 desaturation (eg, O2 saturation below 88 mmHG for more than 5 consecutive minutes)",
"       <strong>",
"        AND",
"       </strong>",
"       symptoms (eg, morning headache, hypersomnolence, etc)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Appropriate diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"1\">",
"       Slowly progressive neuromuscular disease - post-polio syndrome, muscular dystrophy, etc",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Chest wall deformity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Reversible contributing factors treated - heart failure, obstructive sleep apnea, etc",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adequate upper airway function",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13611=[""].join("\n");
var outline_f13_18_13611=null;
var title_f13_18_13612="Clin features NB hypertension";
var content_f13_18_13612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of neonatal hypertension",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Asymptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiorespiratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tachypnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyanosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mottling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased or unequal pulses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lethargy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tremors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertonicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotonicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opisthotonos",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemiparesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracranial hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymmetric reflexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retinopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Renal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal enlargement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium wasting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oligoanuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Failure to thrive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal distention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenal mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13612=[""].join("\n");
var outline_f13_18_13612=null;
var title_f13_18_13613="Chemo nonmet osteosarc POG 8651";
var content_f13_18_13613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemotherapy for nonmetastatic osteosarcoma per pediatric oncology group (POG) trial 8651",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Agents",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Neoadjuvant approach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        0, 1, 5, 6, 13, 14, 18, 19, 23, 24, 37, 38",
"       </td>",
"       <td>",
"        High-dose methotrexate",
"       </td>",
"       <td>",
"        12 grams/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leucovorin rescue",
"       </td>",
"       <td>",
"        15 mg orally or IV every six hours for 10 doses",
"       </td>",
"       <td>",
"        Starting 24 hours after beginning high-dose methotrexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10",
"       </td>",
"       <td colspan=\"3\">",
"        Surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        2, 7, 25, 28",
"       </td>",
"       <td>",
"        Doxorubicin",
"       </td>",
"       <td>",
"        37.5 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day",
"       </td>",
"       <td rowspan=\"2\">",
"        1, 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cisplatin",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        20",
"       </td>",
"       <td>",
"        Doxorubicin",
"       </td>",
"       <td>",
"        30 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day",
"       </td>",
"       <td>",
"        1, 2, 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        15, 31, 34, 39, 42",
"       </td>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day",
"       </td>",
"       <td rowspan=\"3\">",
"        1, 2, 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleomycin",
"       </td>",
"       <td>",
"        15 units/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dactinomycin",
"       </td>",
"       <td>",
"        0.6 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Adjuvant approach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td colspan=\"3\">",
"        Surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        3, 4, 8, 9, 13, 14 18, 19, 23, 24, 37, 38",
"       </td>",
"       <td>",
"        High-dose methotrexate",
"       </td>",
"       <td>",
"        12 grams/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leucovorin rescue",
"       </td>",
"       <td>",
"        15 mg orally or IV every six hours for 10 doses",
"       </td>",
"       <td>",
"        Starting 24 hours after beginning high-dose methotrexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        5, 10, 25, 28",
"       </td>",
"       <td>",
"        Doxorubicin",
"       </td>",
"       <td>",
"        37.5 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day",
"       </td>",
"       <td rowspan=\"2\">",
"        1, 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cisplatin",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        20",
"       </td>",
"       <td>",
"        Doxorubicin",
"       </td>",
"       <td>",
"        30 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day",
"       </td>",
"       <td>",
"        1, 2, 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        15, 31, 34, 39, 42",
"       </td>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day",
"       </td>",
"       <td rowspan=\"3\">",
"        1, 2, 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleomycin",
"       </td>",
"       <td>",
"        15 units/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dactinomycin",
"       </td>",
"       <td>",
"        0.6 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Goorin AM, et al. J Clin Oncol 2003; 21:1574.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13613=[""].join("\n");
var outline_f13_18_13613=null;
var title_f13_18_13614="Algorithm for reoperation for primary hyperparathyroidism";
var content_f13_18_13614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F78548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F78548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 572px\">",
"   <div class=\"ttl\">",
"    Evaluation paradigm for patient undergoing reoperation for primary hyperparathyroidism when no abnormal parathyroid tissue had been previously excised",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 552px; height: 541px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Alexander, HR Jr, Chen, Shawker, T, et al. Role of preoperative localization and intraoperative localization maneuvers including intraoperative PTH assay determination for patients with persistent or recurrent hyperparathyroidism. J Bone Miner Res 2002; 17 Suppl 2:N133. Copyright &copy; 2002 American Society for Bone and Mineral Research.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13614=[""].join("\n");
var outline_f13_18_13614=null;
var title_f13_18_13615="Effects of vitamin D supplementation on total fracture";
var content_f13_18_13615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 665px\">",
"   <div class=\"ttl\">",
"    Meta-analysis of randomized trials comparing the effects of vitamin D supplementation with placebo on total fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 645px; height: 302px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chung M, Lee J, Terasawa T, et al. Vitamin D With or Without Calcium Supplementation for Prevention of Cancer and Fractures: An Updated Meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:827. Copyright &copy; 2011 American College of Physicians. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_18_13615=[""].join("\n");
var outline_f13_18_13615=null;
              